var docs;if (!docs) docs =[]; docs["91"]={"9100":"<p><b>Title</b> Palbociclib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of a strong CYP3A4 inducer with palbociclib.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The palbociclib AUC and maximum serum concentration were an average of 85% and 70% lower, respectively, with concurrent use of the strong CYP3A4 inducer rifampin according to a study in which 14 healthy volunteers received a single dose of palbociclib (125 mg) together with rifampin (600 mg/day).<sup>1</sup> Due to concerns about reduced palbociclib effectiveness resulting from the reduced concentrations, the palbociclib prescribing information recommends avoiding concurrent use of any strong or moderate CYP3A4 inducers with palbociclib.<sup>1</sup><br><br>Palbociclib appears primarily dependent on CYP3A4 and SULT2A1 for its metabolism,<sup>1</sup> making increased palbociclib metabolism due to induction of CYP3A4 the likely mechanism for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ibrance</i> (palbociclib) [prescribing information]. New York, NY: Pfizer Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9101":"<p><b>Title</b> Palbociclib / CYP3A4 Inducers (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The significance and recommended management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced palbociclib effectiveness when used together with a moderate CYP3A4 inducer. While the US label does not provide specific recommendations on use with moderate CYP3A4 inducers, the Canadian label recommends avoiding concomitant use of moderate CYP3A4 inducers with palbociclib.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The palbociclib AUC was an average of 32% lower with concurrent use of the moderate CYP3A4 inducer modafanil according to a study in which 14 healthy volunteers received a single dose of palbociclib (125 mg) together with multiple doses of modafanil (400 mg/day).<sup>1</sup> While the US label does not provide specific recommendations on use with moderate CYP3A4 inducers, the Canadian label recommends avoiding concomitant use of moderate CYP3A4 inducers with palbociclib.<sup>2</sup><br><br>Since palbociclib appears primarily dependent on CYP3A4 and SULT2A1 for its metabolism, the likely mechanism for this interaction is induction of palbociclib metabolism, resulting in decreased palbociclib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ibrance (palbociclib) [prescribing information]. New York, NY: Pfizer Inc; February 2016.</p>\n<p>2. Ibrance (palbociclib) [product monograph]. Kirkland, Quebec: Pfizer Canada Inc.; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9102":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Palbociclib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Palbociclib may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of altered response to the CYP3A4 substrate. Dose adjustment or closer monitoring may be necessary for CYP3A4 substrates with a narrow therapeutic index.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> The AUC and maximum serum concentration of the CYP3A4 substrate midazolam were an average of 61% and 37% higher, respectively, with concurrent use of the palbociclib according to a study in which 26 healthy volunteers received a palbociclib (125 mg/day) together with midazolam.<sup>1</sup> The clinical significance of such interactions is uncertain, but the palbociclib prescribing information cautions that greater care and possible dose reductions of CYP3A4 substrates with a narrow therapeutic index may be needed.<sup>1</sup><br><br>According to the palbociclib prescribing information, palbociclib is a weak time-dependent inhibitor of CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ibrance</i> (palbociclib) [prescribing information]. New York, NY: Pfizer Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9103":"<p><b>Title</b> Palbociclib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Palbociclib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The palbociclib AUC was 62% and 13% lower following coadministration of a single 125 mg dose of palbociclib with multiple doses of the proton pump inhibitor (PPI) rabeprazole under fasted and fed conditions, respectively.<sup>1</sup> As palbociclib is to be administered with food, the impact of this interaction is expected to be minimal.<br><br>The likely mechanism for this apparent interaction is decreased palbociclib solubility with increasing pH. The solubility of palbociclib is significantly reduced at pH values greater than 4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ibrance</i> (palbociclib) [prescribing information]. New York, NY: Pfizer Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9104":"<p><b>Title</b> Tetracyclines / Magnesium Dimecrotate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Magnesium Dimecrotate may interact via an unknown mechanism with Tetracyclines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution if magnesium dimecrotate is combined with a tetracycline antibiotic.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Product labeling for magnesium dimecrotate warns that this drug may interact with tetracyclines. No further information is provided to describe the consequences of this combination or the mechanism by which these agents may interact.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pamdial tablet (magnesium dimecrotate) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200706535. Accessed April 2, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9105":"<p><b>Title</b> Minoxidil (Systemic) / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling warns of increased minoxidil effects with this combination, recommending avoidance or minoxidil dose reduction to avoid hypotension. US labeling does not mention this possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Minoxidil (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased minoxidil effects (eg, hypotension) if combined with atazanavir. Canadian product labeling recommends avoiding this combination or reducing the minoxidil dose. US prescribing information does not warn of this potential interaction.</p> \n<p><b>Discussion</b> Canadian labeling for minoxidil warns that the combination of minoxidil and atazanavir may result in increased minoxidil concentrations and increased effects.<sup>1</sup> Avoidance of this combination or a minoxidil dose reduction accompanied with careful monitoring is recommended.<sup>1</sup> US product labeling for minoxidil does not warn of this potential interaction.<sup>2</sup><br><br>The mechanism of this proposed interaction is that atazanavir is an inhibitor of UDP-glucuronosyltransferase (UGT) 1A1 and UGTs are responsible for the majority of minoxidil metabolism.<sup>1,2,3</sup> The specific UGT isoform(s) responsible for minoxidil metabolism, including the role of UGT 1A1, are unknown.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Loniten</i> (minoxidil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</p>\n<p>2. <i>Loniten</i> (minoxidil) [prescribing information]. New York, NY: Pfizer Inc; January 2015.</p>\n<p>3. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Meyers Squibb Company; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9106":"<p><b>Title</b> Minoxidil (Systemic) / Probenecid</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling warns of increased minoxidil effects with this combination, recommending avoidance or minoxidil dose reduction to avoid hypotension. US labeling does not mention this possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Minoxidil (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased minoxidil effects (eg, hypotension) if combined with probenecid. Canadian product labeling recommends avoiding this combination or reducing the minoxidil dose. US prescribing information does not warn of this potential interaction.</p> \n<p><b>Discussion</b> Canadian labeling for minoxidil warns that the combination of minoxidil and probenecid may result in increased minoxidil concentrations and increased effects.<sup>1</sup> Avoidance of this combination or a minoxidil dose reduction accompanied with careful monitoring is recommended.<sup>1</sup> US product labeling for minoxidil does not warn of this potential interaction.<sup>2</sup><br><br>The mechanism of this proposed interaction is that probenecid is an inhibitor of various UDP-glucuronosyltransferases (UGTs) and UGTs are responsible for the majority of minoxidil metabolism.<sup>1,2,3</sup> The specific UGT isoforms responsible for minoxidil metabolism are unknown.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Loniten</i> (minoxidil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</p>\n<p>2. <i>Loniten</i> (minoxidil) [prescribing information]. New York, NY: Pfizer Inc; January 2015.</p>\n<p>3. Uchaipichat V, Mackenzie PI, Guo XH, et al. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-napthol glucoronidation, effects of organic solvents, and inhibition by diclofenac and probenecid [published correction appears in Drug Metab Dispos. 2005;33(12):1925-1926]. <i>Drug Metab Dispos</i>. 2004;32(4):413-423. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15039294\">[PubMed 15039294]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9108":"<p><b>Title</b> Tamsulosin / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tamsulosin effects (eg, hypotension, orthostasis) if tamsulosin is combined with a strong CYP2D6 inhibitor. Increases in tamsulosin exposure may be greater if a CYP2D6 inhibitor and a CYP3A4 inhibitor are combined with tamsulosin.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 24 healthy volunteers, the strong CYP2D6 inhibitor paroxetine (10 mg daily for 3 days, then 20 mg daily for 9 days) increased the tamsulosin (0.4 mg single dose given on day 11) AUC and maximum serum concentration 1.6-fold and 1.3-fold, respectively.<sup>1,2,3</sup> No changes in blood pressure or heart rate were seen.<sup>3</sup> <br><br>Prescribing information for tamsulosin products states that tamsulosin and CYP2D6 inhibitors should be combined with caution and patients should be monitored for increased tamsulosin effects.<sup>1,2</sup> Although never evaluated in a clinical study, prescribing information also states that increases in tamsulosin exposure may be greater if a CYP2D6 inhibitor and a CYP3A4 inhibitor are combined with tamsulosin.<sup>1,2</sup><br><br>The mechanism of this potential interaction is that CYP2D6 and CYP3A4 are responsible for a significant portion of tamsulosin metabolism. The inhibition of CYP2D6 by strong inhibitors may lead to increased exposure and effects. Similar increases in exposure may also be seen in patients known to be CYP2D6 poor metabolizers and greater increases in exposure may be expected if also combined with a CYP3A4 inhibitor.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Flomax</i> (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; October 2014.</p>\n<p>2. <i>Jalyn</i> (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2015.</p>\n<p>3. Troost J, Tatami S, Tsuda Y, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. <i>Br J Clin Pharmacol</i>. 2011;72(2):247-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21496064\">[PubMed 21496064]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9109":"<p><b>Title</b> Tamsulosin / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Tamsulosin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tamsulosin effects (eg, hypotension, orthostasis) if tamsulosin is combined with cimetidine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers described in tamsulosin product labeling, administration of cimetidine (400 mg every 6 hours for 6 days) increased the tamsulosin (0.4 mg single dose) AUC by 44%.<sup>1,2</sup><br><br>Tamsulosin prescribing information recommends cautious use with cimetidine, particularly when using higher doses (ie, 0.8 mg daily), as increased exposure could lead to increased effects.<sup>1,2</sup><br><br>The mechanism of this potential interaction is that CYP3A4 is responsible for a significant portion of tamsulosin metabolism and that the inhibition of CYP3A4 by cimetidine may lead to increased exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Flomax</i> (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; October 2014.</p>\n<p>2. <i>Jalyn</i> (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9110":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / AzaTHIOprine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> AzaTHIOprine may diminish the therapeutic effect of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required beyond routine monitoring that accompanies the use of nondepolarizing neuromuscular-blocking agents.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> In a clinical study conducted in 39 patients receiving a kidney transplant, the addition of intravenous azathioprine (3 mg/kg) to stable doses of atracurium and pancuronium resulted in small and transient decreases in neuromuscular blockade.<sup>1</sup> No change in blockade was noted when azathioprine was administered with vecuronium.<sup>1</sup> In another analysis of 100 cases of bilateral nephrectomy or renal transplantation, patients who received azathioprine with neuromuscular blockade required more than a 2-fold increase in neuromuscular blocking agent dose when compared to patients who received neuromuscular blocking drugs alone.<sup>2</sup> Data from animal models report conflicting results.<sup>3,4</sup><br><br>Canadian product labeling for azathioprine warns of this potential interaction, while US labeling does not.<sup>5,6</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine. <i>Br J Anaesth</i>. 1987;59(8):995-1003. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2888477\">[PubMed 2888477]</a></p>\n<p>2. Vetten KB. Immunosuppressive therapy and anaesthesia. <i>S Afr Med J</i>. 1973;47(18):767-770. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4267975\">[PubMed 4267975]</a></p>\n<p>3. Dretchen KL, Morgenroth VH 3rd, Standaert FG, Walts LF. Azathioprine: effects on neuromuscular transmission. <i>Anesthesiology</i>. 1976;45(6):604-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=185925\">[PubMed 185925]</a></p>\n<p>4. Chapple DJ, Clark JS, Hughes R. Interaction between atracurium and drugs used in anaesthesia. <i>Br J Anaesth</i>. 1983;55(suppl 1):17S-22S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6688011\">[PubMed 6688011]</a></p>\n<p>5. <i>Imuran</i> (azathioprine) [product monograph]. Concord, Ontario, Canada: Aspri Pharma Canada Inc; January 2015.</p>\n<p>6. <i>Imuran</i> (azathioprine) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9111":"<p><b>Title</b> HYDROcodone / CYP2D6 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors): The significance of this interaction may be greater in patients who are also receiving a CYP3A4 inhibitor or with use of a strong CYP2D6 inhibitor that also inhibits CYP3A4 (e.g., delaviridine, paroxetine, lopinavir, ritonavir, quinidine, or stiripentol).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of HYDROcodone. Specifically, concentrations of hydromorphone may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of reduced analgesic response if using hydrocodone together with a strong CYP2D6 inhibitor. Patients using a CYP2D6 inhibitor that is also an inhibitor of CYP3A4 (e.g., delavirdine, lopinavir, paroxetine, ritonavir, quinidine, stiripentol) may experience greater hydrocodone concentrations and enhanced opioid effects.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In an observational study of patients receiving hydrocodone (n=91), those who were also taking one or more CYP2D6 substrates or inhibitors had lower odds of experiencing what was defined as a clinically significant reduction in pain (at least a 13 mm decreased on a 100 mm visual analog scale measure of pain) (OR=0.33 (95% CI: 0.1 to 0.8)).<sup>1</sup> Similarly, hydrocodone recipients with a genetic lack of functional CYP2D6 (poor metabolizers or PMs) were shown to have more than 7-fold lower hydromorphone concentrations as compared to those with 2 wild-type copies of the gene encoding CYP2D6 in a cohort study of 156 women post-cesarean delivery, and according to the same study, only hydromorphone concentrations (and not hydrocodone concentrations) correlated significantly with pain relief.<sup>2</sup> The strong CYP2D6 inhibitor quinidine was shown to decrease the clearance of hydrocodone to hydromorphone such that their hydromorphone formation was similar to that of genetic PMs.<sup>3</sup><br><br>Conversely, the hydrocodone AUC and maximum serum concentration were not significantly changed when hydrocodone (20 mg single dose) was administered with the strong CYP2D6 inhibitor paroxetine (20 mg/day for 12 days).<sup>4</sup> In another study, the conversion of hydrocodone to hydromorphone was found to be of little or no significance in determining the response to hydrocodone, as measured by both pupil response and subjective ratings, with no significant differences among controls, individuals receiving the CYP2D6 inhibitor quinidine, and genetic PMs.<sup>5</sup> An animal study (in Rhesus monkeys) also found that inhibiting the conversion of hydrocodone to hydromorphone had no significant effect on overall hydrocodone effect.<sup>6</sup><br><br>Given these conflicting findings, the clinical importance of this apparent interaction remains uncertain. Labeling for single-entity hydrocodone products do not specifically caution about concurrent use of even strong CYP2D6 inhibitors, except regarding the use of both a CYP3A4 inhibitor and a CYP2D6 inhibitor.<sup>4,7</sup> The labeling for these products do contain strong warnings about the use of all CYP3A4 inhibitors, as CYP3A4 is primarily responsible for hydrocodone metabolism, mediating its N-demethylation to norhydrocodone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. <i>Acad Emerg Med</i>. 2014;21(8):879-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25156930\">[PubMed 25156930]</a></p>\n<p>2. Stauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro-drug or drug? <i>Clin Chim Acta</i>. 2014;429:26-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24269714\">[PubMed 24269714]</a></p>\n<p>3. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. <i>Clin Pharmacol Ther</i>. 1993;54(5):463-472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7693389\">[PubMed 7693389]</a></p>\n<p>4. <i>Hysingla</i> (hydrocodone) [prescribing information]. Stamford, CT: Purdue Pharma L.P.; November 2014.</p>\n<p>5. Kaplan HL, Busto UE, Baylon GJ, et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. <i>J Pharmacol Exp Ther</i>. 1997;281(1):103-108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9103485\">[PubMed 9103485]</a></p>\n<p>6. Lelas S, Wegert S, Otton SV, Sellers EM, France CP. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. <i>Drug Alcohol Depend</i>. 1999;54(3):239-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10372797\">[PubMed 10372797]</a></p>\n<p>7. <i>Zohydro ER</i> (hydrocodone) [prescribing information]. San Diego, CA: Zogenix, Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9112":"<p><b>Title</b> Fosamprenavir / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Dexamethasone (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use the combination of dexamethasone and fosamprenavir with caution. Monitor for increased dexamethasone effects and reduced efficacy of fosamprenavir.</p> \n<p><b>Discussion</b> No clinical studies have been conducted to evaluate the potential interaction between dexamethasone and fosamprenavir. However, prescribing information for fosamprenavir states that use with dexamethasone may result in decreased amprenavir (the active moiety of the prodrug fosamprenavir) concentrations and lead to a reduction in efficacy.<sup>1</sup> Prescribing information for dexamethasone similarly states that administration of dexamethasone with CYP3A4 substrates (eg, fosamprenavir) may lead to decreased concentrations of the substrate.<sup>2</sup> Dexamethasone prescribing information further notes that use of CYP3A4 inhibitors (eg, fosamprenavir) with dexamethasone may result in increased dexamethasone concentrations and effects.<sup>2</sup><br><br>The mechanism by which dexamethasone may decrease amprenavir concentrations is likely the result of CYP3A4 induction by dexamethasone, an enzyme responsible for the majority of fosamprenavir metabolism. The mechanism by which fosamprenavir may increase dexamethasone is likely the result of CYP3A4 inhibition by fosamprenavir, an enzyme responsible for dexamethasone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lexiva</i> (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2015.</p>\n<p>2. <i>Decadron</i> (dexamethasone) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; May 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9113":"<p><b>Title</b> Simvastatin / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients being treated with simvastatin should avoid ingestion of grapefruit juice. Larger quantities of and more highly concentrated grapefruit juice is of particular concern, but all concurrent use should be avoided to minimize the risk for a significant interaction. Fluvastatin, pitavastatin, pravastatin, and rosuvastatin all appear to be at particularly low risk for any clinically significant interaction with even larger amounts of grapefruit juice and may be suitable alternatives for patients who consume large amounts of grapefruit juice or for patients whose grapefruit juice consumption is highly variable.</p> \n<p><b>Discussion</b> The AUC of simvastatin and simvastatin acid were increased an average of 16- and 7-fold, respectively, with concurrent administration of 200 mL double-strength grapefruit juice (GFJ) three times daily and simvastatin.<sup>1,2</sup> With 200 mL to approximately 237 mL of single-strength GFJ, the simvastatin and simvastatin AUC were increased by 1.9- to 3.6-fold and 1.3- to 3.3-fold, respectively.<sup>1,3</sup><br><br>Animal models also confirm an increase in simvastatin concentration with concurrent administration of GFJ.<sup>4</sup> Of note, the interaction between GFJ and simvastatin persisted for 3 to 7 days after intake of 40 mg of simvastatin and 200 mL of double-strength GFJ three times a day for three days.<sup>5</sup> Simvastatin prescribing information recommends that patients receiving simvastatin should avoid the use of GFJ.<sup>1</sup><br><br>The mechanism of this interaction appears to be predominately related to the ability of some GFJ constituents to inhibit CYP3A4.<sup>6,7,8,9</sup> Some GFJ-mediated alteration in HMG-CoA reductase inhibitor transport (e.g., via p-glycoprotein and/or other efflux or uptake transporters) is also possible.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zocor</i> (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p>2. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. <i>Clin Pharmacol Ther</i>. 1998;64(5):477-483. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9834039\">[PubMed 9834039]</a></p>\n<p>3. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. <i>Br J Clin Pharmacol</i>. 2004;58(1):56-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15206993\">[PubMed 15206993]</a></p>\n<p>4. Butterweck V, Zdrojewski I, Galloway C, Frye R, Derendorf H. Toxicological and pharmacokinetic evaluation of concomitant intake of grapefruit juice and simvastatin in rats after repeated treatment over 28 days. <i>Planta Med</i>. 2009;75(11):1196-1202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19350484\">[PubMed 19350484]</a></p>\n<p>5. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. <i>Clin Pharmacol Ther</i>. 2000;68(4):384-390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11061578\">[PubMed 11061578]</a></p>\n<p>6. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. <i>J Pharmacol Exp Ther</i>. 2005;312(3):1151-1160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15485894\">[PubMed 15485894]</a></p>\n<p>7. Edwards DJ, Bellevue FH 3rd, Woster PM. Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. <i>Drug Metab Dispos</i>. 1996;24(12):1287-1290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8971132\">[PubMed 8971132]</a></p>\n<p>8. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. <i>Drug Metab Dispos</i>. 1997;25(11):1228-1233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9351897\">[PubMed 9351897]</a></p>\n<p>9. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. <i>J Clin Invest</i>. 1997;99(10):2545-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9153299\">[PubMed 9153299]</a></p>\n<p>10. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. <i>Pharmacotherapy</i>. 2006;26(11):1601-1607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17064205\">[PubMed 17064205]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9114":"<p><b>Title</b> Simvastatin / Danazol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Danazol may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of danazol with simvastatin is contraindicated.</p> \n<p><b>Discussion</b> Two published case reports describe patients who experienced rhabdomyolysis that was at least partially attributed to a likely interaction with danazol.<sup>1,2</sup> The simvastatin prescribing information contraindicates concurrent use of danazol with simvastatin.<sup>3</sup><br><br>The specific mechanism of this apparent interaction is unclear, but danazol may inhibit the CYP3A4-mediated metabolism of simvastatin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stankovic I, Vlahovic-Stipac A, Putnikovic B, Cvetkovic Z, Neskovic AN. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. <i>Clin Ther</i>. 2010;32(5):909-914. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20685498\">[PubMed 20685498]</a></p>\n<p>2. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. <i>Can J Clin Pharmacol</i>. 2003;10(4):172-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14712320\">[PubMed 14712320]</a></p>\n<p>3. <i>Zocor</i> (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9115":"<p><b>Title</b> Insulins / Dipeptidyl Peptidase-IV Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dipeptidyl Peptidase-IV Inhibitors may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.</p>\n<div>\n <p><b>Dipeptidyl Peptidase-IV Inhibitors Interacting Members</b> Alogliptin, Anagliptin, Evogliptin, Gemigliptin, Linagliptin, SAXagliptin, SITagliptin, Teneligliptin, Vildagliptin</p>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> Manufacturers of several dipeptidyl peptidase-IV (DPP-IV) inhibitors state that in clinical trials, the incidence of hypoglycemia was greater when DPP-IV inhibitors were combined with insulin compared with the use of insulin alone.<sup>1,2,3</sup> It is recommended to consider insulin dose reductions in patients receiving both agents and to monitor for the development of hypoglycemia.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Januvia</i> (sitagliptin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; October 2013.</p>\n<p>2. <i>Onglyza</i> (saxagliptin) [prescribing information]. Princeton, NJ: Bristol-Meyers Squibb Company; May 2013.</p>\n<p>3. <i>Tradjenta</i> (linagliptin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>4. <i>Nesina</i> (alogliptin) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9116":"<p><b>Title</b> Sulfonylureas / Dipeptidyl Peptidase-IV Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dipeptidyl Peptidase-IV Inhibitors may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.</p>\n<div>\n <p><b>Dipeptidyl Peptidase-IV Inhibitors Interacting Members</b> Alogliptin, Anagliptin, Evogliptin, Gemigliptin, Linagliptin, SAXagliptin, SITagliptin, Teneligliptin, Vildagliptin</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Manufacturers of several dipeptidyl peptidase-IV (DPP-IV) inhibitors state that in clinical trials, the incidence of hypoglycemia was greater when DPP-IV inhibitors were combined with a sulfonylurea compared with the use of a sulfonylurea alone.<sup>1,2,3</sup> A meta-analysis of 10 studies found that the risk of hypoglycemia associated with the combination of a DPP-IV inhibitor and a sulfonylurea was significantly greater than with the use of sulfonylureas alone (RR 1.52, 95% CI [1.29 to 1.80]).<sup>4</sup> Sulfonylurea dose reductions should be considered in patients receiving both agents, and patients should be monitored for hypoglycemia.<sup>1,2,3,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Januvia (sitagliptin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; October 2013.</p>\n<p>2. Onglyza (saxagliptin) [prescribing information]. Princeton, NJ: Bristol-Meyers Squibb Company; May 2013.</p>\n<p>3. Tradjenta (linagliptin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>4. Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis [published online May 3, 2016]. <i>BMJ</i>. doi: 10.1136/bmj.i2231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27142267\">[PubMed 27142267]</a></p>\n<p>5. Nesina (alogliptin) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; January 2013.</p>\n<p>6. Galvus (vildagliptin) [summary of product characteristics]. Frimley, Surrey, UK: Novartis Pharmaceuticals UK Ltd; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9117":"<p><b>Title</b> Amiodarone / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone serum concentrations and effects during concomitant atazanavir treatment.</p> \n<p><b>Discussion</b> Atazanavir US prescribing information recommends additional monitoring of amiodarone serum concentrations when these agents are used together, due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is atazanavir inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9118":"<p><b>Title</b> Amiodarone / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosamprenavir may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone serum concentrations and effects during concomitant fosamprenavir treatment.</p> \n<p><b>Discussion</b> Fosamprenavir US prescribing information recommends additional monitoring of amiodarone serum concentrations when these agents are used together, due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is fosamprenavir inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lexiva</i> (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9119":"<p><b>Title</b> Amiodarone / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may enhance the QTc-prolonging effect of Amiodarone. Lopinavir may increase the serum concentration of Amiodarone. More specifically, Lopinavir/Ritonavir may increase the serum concentration of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of amiodarone and lopinavir/ritonavir. If this combination cannot be avoided, monitor for increased amiodarone serum concentrations and effects as well as for evidence of QT interval prolongation.</p> \n<p><b>Discussion</b> Lopinavir/ritonavir US prescribing information recommends additional monitoring of amiodarone serum concentrations when these agents are used together, due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> It also states that lopinavir/ritonavir use should be avoided in combination with other drugs that prolong QT interval. The suspected primary mechanisms of interaction between these agents are inhibition of CYP3A-mediated amiodarone metabolism and enhancement of amiodarone QT prolonging effects by ritonavir and/or lopinavir. The warnings associated with lopinavir/ritonavir contrast slightly with those in US prescribing information for ritonavir alone, which lists concurrent amiodarone use as contraindicated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>2. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9120":"<p><b>Title</b> Amiodarone / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone serum concentrations and effects during concomitant darunavir treatment.</p> \n<p><b>Discussion</b> Darunavir US prescribing information recommends additional monitoring of amiodarone serum concentrations when these agents are used together, due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is darunavir inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Prezista</i> (darunavir) [prescribing information]. Titusville NJ: Janssen Products LP; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9121":"<p><b>Title</b> Amiodarone / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Indinavir may increase the serum concentration of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of indinavir and amiodarone. Indinavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Indinavir US prescribing information lists its combination with amiodarone as contraindicated due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is indinavir inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Crixivan</i> (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9122":"<p><b>Title</b> Amiodarone / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nelfinavir may increase the serum concentration of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of nelfinavir and amiodarone. Nelfinavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Nelfinavir US prescribing information lists its combination with amiodarone as contraindicated due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is nelfinavir inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Viracept</i> (nelfinavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare Company; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9123":"<p><b>Title</b> Amiodarone / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ritonavir and amiodarone. Ritonavir US prescribing information lists this combination as contraindicated. Amiodarone use should be avoided with lopinavir/ritonavir, but if the combination must be used, monitor closely for increased amiodarone serum concentrations and effects.</p> \n<p><b>Discussion</b> Ritonavir US prescribing information lists its combination with amiodarone as contraindicated due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is ritonavir inhibition of CYP3A-mediated amiodarone metabolism. The warnings associated with ritonavir alone contrast slightly with those in US prescribing information for lopinavir/ritonavir, which in one section recommends only additional monitoring of amiodarone serum concentrations when these agents are used together but in another recommends avoiding its use in combination with agents that prolong QT interval.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>2. <i>Kaletra</i> (lopinavir and ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9124":"<p><b>Title</b> Amiodarone / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the QTc-prolonging effect of Amiodarone. Saquinavir may increase the serum concentration of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of saquinavir and amiodarone. Saquinavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Saquinavir US prescribing information lists its combination with amiodarone as contraindicated due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is saquinavir inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invirase</i> (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9125":"<p><b>Title</b> Amiodarone / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tipranavir and amiodarone. Tipranavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Tipranavir US prescribing information lists its combination with amiodarone as contraindicated due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is inhibition of CYP3A-mediated amiodarone metabolism by tipranavir and/or coadministered ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc: April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9126":"<p><b>Title</b> Amiodarone / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased amiodarone serum concentrations and effects during concomitant cobicistat treatment.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products recommends additional monitoring of amiodarone serum concentrations when these agents are used together, due to the potential for elevated serum amiodarone concentrations and associated toxicity.<sup>1,2,3,4</sup> The suspected primary mechanism of interaction between these agents is cobicistat inhibition of CYP3A-mediated amiodarone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9127":"<p><b>Title</b> Bradycardia-Causing Agents / Ruxolitinib</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible, while US labeling does not mention the possible interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ruxolitinib may enhance the bradycardic effect of Bradycardia-Causing Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for bradycardia and increases in PR interval if ruxolitinib is combined with other bradycardia-causing agents. Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to the ruxolitinib Canadian product monograph, in placebo-controlled phase 3 clinical trials, treatment with ruxolitinib was associated with statistically significant 6 to 8 beat per minute reductions in heart rate and 6 to 9 millisecond increases in the PR interval compared with placebo.<sup>1</sup> Canadian labeling recommends avoiding use of ruxolitinib with other agents that lower heart rate and/or prolong PR interval to the extent possible.<sup>1</sup> US labeling does not mention bradycardia or a prolonged PR interval as observed adverse effects of ruxolitinib and does not suggest any specific action when combined with other bradycardia-causing agents.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Jakavi</i> (ruxolitinib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; December 2014.</p>\n<p>2. <i>Jakafi</i> (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9128":"<p><b>Title</b> Saquinavir / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Saquinavir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased saquinavir toxicity/effects if combined with bitter orange.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 20 healthy volunteers, the mean saquinavir (600 mg single dose) clearance decreased 40% and the maximum serum concentration increased 98% when coadministered with 240 mL of Seville orange juice (bitter orange).<sup>1</sup> The effect was highly variable, as 6 subjects experienced an increase in saquinavir clearance.<sup>2</sup><br><br>The probable mechanism of this interaction is inhibition of intestinal CYP3A4 by bitter orange (Seville orange), an enzyme responsible for saquinavir metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. <i>Clin Pharmacol Ther</i>. 2005;78(6):605-618. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16338276\">[PubMed 16338276]</a></p>\n<p>2. <i>Invirase</i> (saquinavir) [prescribing information].South San Francisco, CA: Genetech USA Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9129":"<p><b>Title</b> Felodipine / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Felodipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of felodipine (eg, hypotension) if combined with bitter orange.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 10 healthy volunteers, the AUC and maximum serum concentration of felodipine (10 mg extended release single dose) increased 76% and 61%, respectively, when coadministered with 240 mL of Seville orange juice (bitter orange).<sup>1</sup><br><br>The probable mechanism of this interaction is inhibition of intestinal CYP3A4 by bitter orange, an enzyme responsible for felodipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. <i>Clin Pharmacol Ther</i>. 2001;69(1):14-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180034\">[PubMed 11180034]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9130":"<p><b>Title</b> MethylPREDNISolone / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In one study, the pharmacokinetic parameters of methylprednisolone (40 mg/1.73 m<sup>2</sup> single IV dose) were compared between 15 children who were taking CYP3A4 inducers (phenytoin, phenobarbital, or carbamazepine) and 9 children who were not taking CYP3A4 inducers.<sup>1</sup> The clearance of methylprednisolone was 3.1-fold to 5.8-fold greater, and the half-life was 54% to 71% shorter, in the children taking CYP3A4 inducers.<sup>1</sup> In another study of 8 healthy volunteers, the administration of phenytoin (300 mg daily for 3 weeks) or phenobarbital (120 mg daily for 3 weeks) increased the clearance of methylprednisolone (single IV dose) 2.3-fold and 1.9-fold, respectively.<sup>2</sup> Lastly, a case report describes a patient with steroid-dependent asthma who was stable on methylprednisolone 8 mg daily.<sup>3</sup> Within one month of initiating rifampin (a strong CYP3A4 inducer), he experienced 2 asthma exacerbations requiring emergency department visits and a decline in forced expiratory volume exhaled in 1 second (FEV<sub>1</sub>). His asthma control and FEV<sub>1</sub> returned to baseline after rifampin discontinuation.<sup>3</sup> <br><br>Prescribing information for methylprednisolone states that CYP3A4 inducers may enhance the metabolism of methylprednisolone and that dose increases may be required.<sup>4</sup><br><br>Although not fully investigated, the likely mechanism of this interaction is CYP3A4 induction resulting in decreased methylprednisolone exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. <i>Clin Pharmacol Ther</i>. 1987;42(4):424-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3665340\">[PubMed 3665340]</a></p>\n<p>2. Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. <i>J Clin Endocrinol Metab</i>. 1975;41(5):887-893. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1184723\">[PubMed 1184723]</a></p>\n<p>3. Lin FL. Rifampin-induced deterioration in steroid-dependent asthma. <i>J Allergy Clin Immunol</i>. 1996;98(6 pt 1):1125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8977517\">[PubMed 8977517]</a></p>\n<p>4. <i>Solu-Medrol</i> (methylprednisolone) [prescribing information]. New York, NY: Pfizer Inc; May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9131":"<p><b>Title</b> PredniSONE / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased prednisone effects if combined with a strong CYP3A4 inducer. Increases in prednisone dose may be required to maintain steroid effectiveness.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies have evaluated the effect of a course of the strong CYP3A4 inducer rifampin on the pharmacokinetics of prednisolone (the active metabolite of prednisone).<sup>1,2,3,4,5</sup> Prednisolone clearance increased 37% to 94%, half-life decreased 39% to 45%, and the AUC decreased 28% to 66%.<sup>1,2,3,4,5</sup> Similar changes in prednisolone pharmacokinetics were observed in studies evaluating the combination of prednisolone and phenytoin.<sup>6,7,8</sup> Prednisolone clearance increased 44% to 77%, half-life decreased 29% to 45% and the AUC decreased 30%.<sup>6,7,8</sup> Prednisolone clearance increased 41% and 79%, respectively, with the administration of phenobarbital and carbamazepine.<sup>6</sup> Other reports have shown that the prednisolone clearance was 42% to 44% greater, and half-life 27% to 32% shorter, in patients taking carbamazepine, phenobarbital, or phenytoin compared with control groups not taking a CYP3A4 inducer.<sup>7,8</sup> In support of these studies, numerous reports describe patients who experienced a decrease in, or absence of, prednisone or prednisolone effectiveness with the concomitant use of a CYP3A4 inducer.<sup>2,3,9,10,11,12,13,14,15,16,17,18,19,20,21,22</sup><br><br>Prescribing information for prednisone states that CYP3A4 inducers may increase the clearance of prednisone and that dose increases may be required.<sup>23</sup><br><br>The mechanism of this interaction has not been fully investigated, but CYP3A4 induction resulting in increased prednisone metabolism may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. <i>Eur J Clin Pharmacol</i>. 1993;45(3):287-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8276057\">[PubMed 8276057]</a></p>\n<p>2. Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J. Adverse effect of rifampicin administration on steroid-dependent asthma. <i>Am Rev Respir Dis</i>. 1983;128(2):307-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6349444\">[PubMed 6349444]</a></p>\n<p>3. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. <i>Br Med J (Clin Res Ed)</i>. 1983;286(6369):923-925. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6403136\">[PubMed 6403136]</a></p>\n<p>4. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. <i>Acta Med Scand</i>. 1983;213(5):339-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6880856\">[PubMed 6880856]</a></p>\n<p>5. Bergrem H, Refvem OK. Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. <i>Proc Eur Dial Transplant Assoc</i>. 1983;19:552-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6878255\">[PubMed 6878255]</a></p>\n<p>6. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. <i>Clin Pharmacol Ther</i>. 1987;42(4):424-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3665340\">[PubMed 3665340]</a></p>\n<p>7. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. <i>Clin Pharmacol Ther</i>. 1977;22(6):912-916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=923186\">[PubMed 923186]</a></p>\n<p>8. Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. <i>Eur J Clin Invest</i>. 1984;14(1):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6230241\">[PubMed 6230241]</a></p>\n<p>9. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. <i>Biomed Pharmacother</i>. 1986;40(8):301-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3814762\">[PubMed 3814762]</a></p>\n<p>10. Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. <i>Kidney Int</i>. 1984;25(1):119-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6374250\">[PubMed 6374250]</a></p>\n<p>11. Brooks PM, Buchanan WW, Grove M, Downie WW. Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. <i>Ann Rheum Dis</i>. 1976;35(4):339-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=970991\">[PubMed 970991]</a></p>\n<p>12. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. <i>Arch Intern Med</i>. 1994;154(13):1521-1524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8018008\">[PubMed 8018008]</a></p>\n<p>13. Udwadia ZF, Sridhar G, Beveridge CJ, Soutar C, McHardy GJ, Leitch AG. Catastrophic deterioration in asthma induced by rifampicin in steroid-dependent asthma. <i>Respir Med</i>. 1993;87(8):629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8290748\">[PubMed 8290748]</a></p>\n<p>14. van Marle W, Woods KL, Beeley L. Concurrent steroid and rifampicin therapy. <i>Br Med J</i>. 1979;1(6169):1020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=435934\">[PubMed 435934]</a></p>\n<p>15. Hendrickse W, McKiernan J, Pickup M, Lowe J. Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome. <i>Br Med J</i>. 1979;1(6159):306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=421090\">[PubMed 421090]</a></p>\n<p>16. Dhanoa J, Natu M, Massey S. Worsening of steroid depending bronchial asthma following rifampicin administration. <i>J Assoc Physicians India</i>. 1998;46(2):242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11273129\">[PubMed 11273129]</a></p>\n<p>17. Verma M, Singh T, Chhatwal J, Saini V, Pawar B. Rifampicin induced steroid unresponsiveness in nephrotic syndrome. <i>Indian Pediatr</i>. 1994;31(11):1437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7896353\">[PubMed 7896353]</a></p>\n<p>18. Jain NK, Madan A, Jhamaria JP, Sharma TN, Mathur DK, Singh DP. Rifampicin induced non-responsiveness to steroids in bronchial asthma. <i>Indian J Chest Dis Allied Sci</i>. 1989;31(4):271-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2638668\">[PubMed 2638668]</a></p>\n<p>19. Sehgal VN, Srivastava G. Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy. <i>Int J Dermatol</i>. 1988;27(4):258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3391717\">[PubMed 3391717]</a></p>\n<p>20. Honeybourne D, Longworth S, Shaffer J. Rifampicin causing an exacerbation of pemphigus. <i>Br J Clin Pract</i>. 1987;41(9):937-938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3451779\">[PubMed 3451779]</a></p>\n<p>21. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. <i>J Clin Endocrinol Metab</i>. 1984;59(6);1204-1206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6490796\">[PubMed 6490796]</a></p>\n<p>22. Wassner SJ, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN. Allograft survival in patients receiving anticonvulsant medications. <i>Clin Nephrol</i>. 1977;8(1):293-297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=328199\">[PubMed 328199]</a></p>\n<p>23. Prednisone [prescribing information]. Columbus, OH: Roxane Laboratories Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9132":"<p><b>Title</b> PrednisoLONE (Systemic) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased prednisolone effects if combined with a strong CYP3A4 inducer. Increases in prednisolone dose may be required to maintain steroid effectiveness.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies have evaluated the effect of a course of the strong CYP3A4 inducer rifampin on the pharmacokinetics of prednisolone.<sup>1,2,3,4,5</sup> Prednisolone clearance increased 37% to 94%, half-life decreased 39% to 45%, and the AUC decreased 28% to 66%.<sup>1,2,3,4,5</sup> Similar changes in prednisolone pharmacokinetics were observed in studies evaluating the combination of prednisolone and phenytoin.<sup>6,7,8</sup> Prednisolone clearance increased 44% to 77%, half-life decreased 29% to 45% and the AUC decreased 30%.<sup>6,7,8</sup> Prednisolone clearance increased 41% and 79%, respectively, with the administration of phenobarbital and carbamazepine.<sup>6</sup> Other reports have shown that the prednisolone clearance was 42% to 44% greater, and half-life 27% to 32% shorter, in patients taking carbamazepine, phenobarbital, or phenytoin compared with control groups not taking a CYP3A4 inducer.<sup>7,8</sup> In support of these studies, numerous reports describe patients who experienced a decrease in, or absence of, prednisone or prednisolone effectiveness with the concomitant use of a CYP3A4 inducer.<sup>2,3,9,10,11,12,13,14,15,16,17,18,19,20,21,22</sup><br><br>Prescribing information for prednisolone states that CYP3A4 inducers may increase the clearance of prednisolone and that dose increases may be required.<sup>23</sup><br><br>The mechanism of this interaction has not been fully investigated, but CYP3A4 induction resulting in increased prednisolone metabolism may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. <i>Eur J Clin Pharmacol</i>. 1993;45(3):287-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8276057\">[PubMed 8276057]</a></p>\n<p>2. Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J. Adverse effect of rifampicin administration on steroid-dependent asthma. <i>Am Rev Respir Dis</i>. 1983;128(2):307-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6349444\">[PubMed 6349444]</a></p>\n<p>3. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. <i>Br Med J (Clin Res Ed)</i>. 1983;286(6369):923-925. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6403136\">[PubMed 6403136]</a></p>\n<p>4. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. <i>Acta Med Scand</i>. 1983;213(5):339-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6880856\">[PubMed 6880856]</a></p>\n<p>5. Bergrem H, Refvem OK. Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. <i>Proc Eur Dial Transplant Assoc</i>. 1983;19:552-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6878255\">[PubMed 6878255]</a></p>\n<p>6. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. <i>Clin Pharmacol Ther</i>. 1987;42(4):424-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3665340\">[PubMed 3665340]</a></p>\n<p>7. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. <i>Clin Pharmacol Ther</i>. 1977;22(6):912-916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=923186\">[PubMed 923186]</a></p>\n<p>8. Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. <i>Eur J Clin Invest</i>. 1984;14(1):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6230241\">[PubMed 6230241]</a></p>\n<p>9. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. <i>Biomed Pharmacother</i>. 1986;40(8):301-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3814762\">[PubMed 3814762]</a></p>\n<p>10. Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. <i>Kidney Int</i>. 1984;25(1):119-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6374250\">[PubMed 6374250]</a></p>\n<p>11. Brooks PM, Buchanan WW, Grove M, Downie WW. Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. <i>Ann Rheum Dis</i>. 1976;35(4):339-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=970991\">[PubMed 970991]</a></p>\n<p>12. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. <i>Arch Intern Med</i>. 1994;154(13):1521-1524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8018008\">[PubMed 8018008]</a></p>\n<p>13. Udwadia ZF, Sridhar G, Beveridge CJ, Soutar C, McHardy GJ, Leitch AG. Catastrophic deterioration in asthma induced by rifampicin in steroid-dependent asthma. <i>Respir Med</i>. 1993;87(8):629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8290748\">[PubMed 8290748]</a></p>\n<p>14. van Marle W, Woods KL, Beeley L. Concurrent steroid and rifampicin therapy. <i>Br Med J</i>. 1979;1(6169):1020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=435934\">[PubMed 435934]</a></p>\n<p>15. Hendrickse W, McKiernan J, Pickup M, Lowe J. Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome. <i>Br Med J</i>. 1979;1(6159):306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=421090\">[PubMed 421090]</a></p>\n<p>16. Dhanoa J, Natu M, Massey S. Worsening of steroid depending bronchial asthma following rifampicin administration. <i>J Assoc Physicians India</i>. 1998;46(2):242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11273129\">[PubMed 11273129]</a></p>\n<p>17. Verma M, Singh T, Chhatwal J, Saini V, Pawar B. Rifampicin induced steroid unresponsiveness in nephrotic syndrome. <i>Indian Pediatr</i>. 1994;31(11):1437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7896353\">[PubMed 7896353]</a></p>\n<p>18. Jain NK, Madan A, Jhamaria JP, Sharma TN, Mathur DK, Singh DP. Rifampicin induced non-responsiveness to steroids in bronchial asthma. <i>Indian J Chest Dis Allied Sci</i>. 1989;31(4):271-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2638668\">[PubMed 2638668]</a></p>\n<p>19. Sehgal VN, Srivastava G. Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy. <i>Int J Dermatol</i>. 1988;27(4):258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3391717\">[PubMed 3391717]</a></p>\n<p>20. Honeybourne D, Longworth S, Shaffer J. Rifampicin causing an exacerbation of pemphigus. <i>Br J Clin Pract</i>. 1987;41(9):937-938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3451779\">[PubMed 3451779]</a></p>\n<p>21. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. <i>J Clin Endocrinol Metab</i>. 1984;59(6);1204-1206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6490796\">[PubMed 6490796]</a></p>\n<p>22. Wassner SJ, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN. Allograft survival in patients receiving anticonvulsant medications. <i>Clin Nephrol</i>. 1977;8(1):293-297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=328199\">[PubMed 328199]</a></p>\n<p>23. <i>Orapred</i> (prednisolone) [prescribing information]. Florham Park, NJ: Shionogi Inc; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9133":"<p><b>Title</b> Hydrocortisone (Systemic) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased hydrocortisone effects if combined with a strong CYP3A4 inducer. Increases in hydrocortisone dose may be required to maintain steroid effectiveness.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 3 patients, when hydrocortisone (10 mg twice daily for 2 doses) was given after a course of rifampin therapy (600 mg daily for 10 days) the hydrocortisone clearance increased 38%, the half-life decreased 35%, and the AUC decreased 23%.<sup>1</sup> Several case reports describe the loss of hydrocortisone efficacy, resulting in the development of adrenal insufficiency<sup>2,3,4,5</sup> or an asthma exacerbation<sup>6</sup>, in hydrocortisone treated patients after the addition of various CYP3A4 inducers. Increases in hydrocortisone dose or discontinuation of the CYP3A4 inducer was needed to regain steroid effectiveness in all cases.<sup>2,3,4,5,6</sup><br><br>Prescribing information for hydrocortisone states that CYP3A4 inducers may increase the clearance of hydrocortisone and that dose increases may be required.<sup>7</sup><br><br>The mechanism of this interaction has not been fully investigated, but CYP3A4 induction resulting in increased hydrocortisone metabolism likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. <i>J Clin Endocrinol Metab</i>. 1984;59(6):1204-1206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6490796\">[PubMed 6490796]</a></p>\n<p>2. Kara C, Ucakturk A, Aydin OF, Aydin M. Adverse effect of phenytoin on glucocorticoid replacement in a child with adrenal insufficiency. <i>J Pediatr Endocrinol Metab</i>. 2010;23(9):963-966. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21175098\">[PubMed 21175098]</a></p>\n<p>3. Hogler W, Wudy SA, Luef G, Hartmann MF, Rauchenzauner M. Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction. <i>Arch Dis Child</i>. 2010;95(12):1065. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20515961\">[PubMed 20515961]</a></p>\n<p>4. Maisey DN, Brown RC, Day JL. Letter: Rifampicin and cortisone replacement therapy. <i>Lancet</i>. 1974;2(7885):896-897. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4137806\">[PubMed 4137806]</a></p>\n<p>5. Edwards OM, Courtenay-Evans RJ, Galley JM, Hunter J, Tait AD. Changes in cortisol metabolism following rifampicin therapy. <i>Lancet</i>. 1974;2(7880):548-551. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4140269\">[PubMed 4140269]</a></p>\n<p>6. Jain NK, Madan A, Jhamaria JP, Sharma TN, Mathur DK, Singh DP. Rifampicin induced non-responsiveness to steroids in bronchial asthma. <i>Indian J Chest Dis Allied Sci</i>. 1989;31(4):271-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2638668\">[PubMed 2638668]</a></p>\n<p>7. <i>Solu-Cortef</i> (hydrocortisone) [prescribing information]. New York, NY: Pfizer Inc; August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9134":"<p><b>Title</b> Dexamethasone (Systemic) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Dexamethasone (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 11 asthmatic patients, phenobarbital (30 mg four times per day for 3 weeks) increased the dexamethasone (single IV dose) clearance 87% and decreased the half-life 45%.<sup>1</sup> In a pharmacokinetic study conducted in 9 healthy volunteers, 3 weeks of phenytoin treatment increased dexamethasone (single IV dose) clearance 140% and decreased the half-life 51%<sup>2</sup> In another study conducted in 16 patients with various neurological diseases taking dexamethasone, the clearance of dexamethasone was 193% higher in those receiving phenytoin compared with those taking dexamethasone alone.<sup>3</sup> Numerous case reports describe the loss of dexamethasone effectiveness resulting in a variety of clinical consequences (eg, lupus flare, adrenal insufficiency, cerebral edema) when a strong CYP3A4 inducer (ie, phenytoin, carbamazepine, or primidone) was initiated.<sup>4,5,6,7</sup> Another report describes a patient who experienced an increase in dexamethasone adverse effects (eg, weight gain) when primidone was discontinued.<sup>8</sup> A dexamethasone dose adjustment or discontinuation of the CYP3A4 inducer was required to achieve the previous dexamethasone effects in all cases.<sup>4,5,6,7,8</sup> Numerous reports also describe erroneous results obtained during dexamethasone suppression testing in patients taking strong CYP3A4 inducers, likely as a result of reduced dexamethasone concentrations and effects.<sup>9,10,11,12,13,14,15,16,17,18,19,20</sup> <br><br>Prescribing information for dexamethasone states that CYP3A4 inducers may enhance the metabolism of dexamethasone and that dose increases may be required.<sup>21</sup><br><br>Although not fully investigated, the likely mechanism of this interaction is CYP3A4 induction resulting in decreased dexamethasone exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. <i>N Engl J Med</i>. 1972;286(21):1125-1128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4553339\">[PubMed 4553339]</a></p>\n<p>2. Haque N, Thrasher K, Werk EE Jr, Knowles HC Jr, Sholiton LJ. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. <i>J Clin Endocrinol Metab</i>. 1972;34(1):44-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5008232\">[PubMed 5008232]</a></p>\n<p>3. Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(10):1087-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502166\">[PubMed 6502166]</a></p>\n<p>4. McLelland J, Jack W. Phenytoin/dexamethasone interaction: A clinical problem. <i>Lancet</i>. 1978;1(8073):1096-1097. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=77390\">[PubMed 77390]</a></p>\n<p>5. Boylan JJ, Owen DS, Chin JB. Letter: Phenytoin interference with dexamethasone. <i>JAMA</i>. 1976;235(8):803-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=946303\">[PubMed 946303]</a></p>\n<p>6. Gullo D, Gelsomino R, Marturano I, et al. The antiepileptic drug carbamazepine can cause adrenal insufficiency in patients under hormone replacement therapy for congenital adrenal hyperplasia. <i>Hormones (Athens)</i>. 2013;12(3):470-471. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24121390\">[PubMed 24121390]</a></p>\n<p>7. Hancock KW, Levell MJ. Primidone/dexamethasone interaction. <i>Lancet</i>. 1978;2(8080):97-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=78317\">[PubMed 78317]</a></p>\n<p>8. Young MC, Hughes IA. Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone. <i>Acta Paediatr Scand</i>. 1991;80(1):120-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2028784\">[PubMed 2028784]</a></p>\n<p>9. Abdullah HN, Nowalid WK. Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome. <i>Endokrynol Pol</i>. 2010;61(6):706-709. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21104646\">[PubMed 21104646]</a></p>\n<p>10. Tiong K, Falhammar H. Carbamazepine and falsely positive screening tests for Cushing's syndrome. <i>N Z Med J</i>. 2009;122(1288):100-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19182847\">[PubMed 19182847]</a></p>\n<p>11. Ma RC, Chan WB, So WY, Tong PC, Chan JC, Chow CC. Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome. <i>BMJ</i>. 2005;330(7486):299-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15695278\">[PubMed 15695278]</a></p>\n<p>12. Debrunner J, Schmid C, Schneemann M. Falsely positive dexamethasone suppression test in a patient treated with phenytoin to prevent seizures due to nocardia brain abscesses. <i>Swiss Med Wkly</i>. 2002;132(19-20):267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12148082\">[PubMed 12148082]</a></p>\n<p>13. Zawawi TH, al-Hadramy MS, Abdelwahab SM. The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing's syndrome. <i>Ir J Med Sci</i>. 1996;165(4):300-302. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8990663\">[PubMed 8990663]</a></p>\n<p>14. Terzolo M, Borretta G, Ali A, et al. Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. <i>Horm Metab Res</i>. 1995;27(3):148-150. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7607605\">[PubMed 7607605]</a></p>\n<p>15. Kyriazopoulou V, Vagenakis AG. Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. <i>J Clin Endocrinol Metab</i>. 1992;75(1):315-317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1619024\">[PubMed 1619024]</a></p>\n<p>16. Keitner GI, Fruzzetti AE, Miller IW, Norman WH, Brown WA. The effect of anticonvulsants on the dexamethasone suppression test. <i>Can J Psychiatry</i>. 1989;34(5):441-443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2766197\">[PubMed 2766197]</a></p>\n<p>17. Privitera MR, Greden JF, Gardner RW, Ritchie JC, Carroll BJ. Interference by carbamazepine with the dexamethasone suppression test. <i>Biol Psychiatry</i>. 1982;17(5):611-620. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7093397\">[PubMed 7093397]</a></p>\n<p>18. Meikle AW, Stanchfield JB, West CD, Tyler FH. Hydrocortisone suppression test for Cushing syndrome. Therapy with anticonvulsants. <i>Arch Intern Med </i>. 1974;134(6):1068-1071. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4372963\">[PubMed 4372963]</a></p>\n<p>19. Jubiz W, Meikle AW, Levinson RA, Mizutani S, West CD, Tyler FH. Effect of diphenylhydantoin on the metabolism of dexamethasone. <i>N Engl J Med</i>. 1970;283(1):11-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4315902\">[PubMed 4315902]</a></p>\n<p>20. Werk EE Jr, Choi Y, Sholiton L, Olinger C, Haque N. Interference in the effect of dexamethasone by diphenylhydantoin. <i>N Engl J Med</i>. 1969;281(1):32-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5814988\">[PubMed 5814988]</a></p>\n<p>21. Dexamethasone [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9135":"<p><b>Title</b> Phenytoin / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of Phenytoin. Dexamethasone (Systemic) may increase the serum concentration of Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider dexamethasone dose increases when combined with phenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely when combined with dexamethasone. Both increased and decreased phenytoin levels have been reported, though decreases in phenytoin levels have been reported more frequently.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 9 healthy volunteers, 3 weeks of phenytoin treatment increased dexamethasone (single IV dose) clearance 140% and decreased the half-life 51%<sup>1</sup> In a study conducted in 16 patients with various neurological diseases taking dexamethasone, the clearance of dexamethasone was 193% higher in those receiving phenytoin compared with those taking dexamethasone alone.<sup>2</sup> In support of these studies, case reports describe the loss of dexamethasone effectiveness, resulting in cerebral edema or a lupus flare, upon initiation of phenytoin therapy.<sup>3,4</sup><br><br>Data also suggest that dexamethasone may affect the pharmacokinetics of phenytoin. In one retrospective review of 6 patients, serum phenytoin concentrations prior to initiation of dexamethasone were 2.1-fold greater than after dexamethasone therapy while a stable dose of phenytoin was maintained.<sup>5</sup> Two case reports also describe an inability to achieve therapeutic phenytoin concentrations in patients taking dexamethasone.<sup>6,7</sup> Maintenance phenytoin doses of 800 to 1,000 mg/day were needed to obtain the desired serum level.<sup>6,7</sup> In contrast, a retrospective observation of 38 patients with neurological diseases noted that average serum phenytoin concentrations were significantly higher in those who received both dexamethasone and phenytoin compared with those who received phenytoin alone (17 vs 12 micrograms/mL; <i>P</i> less than 0.001).<sup>8</sup><br><br>Prescribing information for dexamethasone states that phenytoin may enhance the metabolism of dexamethasone and that dose increases may be required.<sup>9</sup> The prescribing information also states that both increases and decreases in phenytoin concentration have been reported with concomitant use of these agents.<sup>9</sup><br><br>Although not fully investigated, the likely mechanism by which phenytoin decreases dexamethasone levels is phenytoin induction of CYP3A4, an enzyme likely responsible for dexamethasone metabolism. Similarly, dexamethasone induction of CYP3A4 is the likely mechanism for the observed decrease in phenytoin levels. The mechanism by which dexamethasone may increase phenytoin levels is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Haque N, Thrasher K, Werk EE Jr, Knowles HC Jr, Sholiton LJ. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. <i>J Clin Endocrinol Metab</i>. 1972;34(1):44-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5008232\">[PubMed 5008232]</a></p>\n<p>2. Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(10):1087-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502166\">[PubMed 6502166]</a></p>\n<p>3. McLelland J, Jack W. Phenytoin/dexamethasone interaction: A clinical problem. <i>Lancet</i>. 1978;1(8073):1096-1097. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=77390\">[PubMed 77390]</a></p>\n<p>4. Boylan JJ, Owen DS, Chin JB. Letter: Phenytoin interference with dexamethasone. <i>JAMA</i>. 1976;235(8):803-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=946303\">[PubMed 946303]</a></p>\n<p>5. Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M. Phenytoin-dexamethasone: a possible drug-drug interaction. <i>JAMA</i>. 1985;254(15):2062-2063. [4046133]</p>\n<p>6. Recuenco I, Espinosa E, Garcia B, Carcas A. Effect of dexamethasone on the decrease of serum phenytoin concentrations. <i>Ann Pharmacother</i>. 1995;29(9):935. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8547745\">[PubMed 8547745]</a></p>\n<p>7. Lackner TE. Interaction of dexamethasone with phenytoin. <i>Pharmacotherapy</i>. 1991;11(4):344-347. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1923918\">[PubMed 1923918]</a></p>\n<p>8. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB. Phenytoin-dexamethasone interaction: a previously unreported observation. <i>Surg Neurol</i>. 1981;16(1):23-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7280966\">[PubMed 7280966]</a></p>\n<p>9. Dexamethasone [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9136":"<p><b>Title</b> Fosphenytoin / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of Fosphenytoin. Dexamethasone (Systemic) may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider dexamethasone dose increases when combined with fosphenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely. Both increased and decreased phenytoin levels have been reported, though decreases in phenytoin levels have been reported more frequently.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 9 healthy volunteers, 3 weeks of phenytoin treatment increased dexamethasone (single IV dose) clearance 140% and decreased the half-life 51%<sup>1</sup> In a study conducted in 16 patients with various neurological diseases taking dexamethasone, the clearance of dexamethasone was 193% higher in those receiving phenytoin compared with those taking dexamethasone alone.<sup>2</sup> In support of these studies, case reports describe the loss of dexamethasone effectiveness, resulting in cerebral edema or a lupus flare, upon initiation of phenytoin therapy.<sup>3,4</sup><br><br>Data also suggest that dexamethasone may affect the pharmacokinetics of phenytoin. In one retrospective review of 6 patients, serum phenytoin concentrations prior to initiation of dexamethasone were 2.1-fold greater than after dexamethasone therapy while a stable dose of phenytoin was maintained.<sup>5</sup> Two case reports also describe an inability to achieve therapeutic phenytoin concentrations in patients taking dexamethasone.<sup>6,7</sup> Maintenance phenytoin doses of 800 to 1,000 mg/day were needed to obtain the desired serum level.<sup>6,7</sup> In contrast, a retrospective observation of 38 patients with neurological diseases noted that average serum phenytoin concentrations were significantly higher in those who received both dexamethasone and phenytoin compared with those who received phenytoin alone (17 vs 12 micrograms/mL; <i>P</i> less than 0.001).<sup>8</sup><br><br>Prescribing information for dexamethasone states that phenytoin may enhance the metabolism of dexamethasone and that dose increases may be required.<sup>9</sup> The prescribing information also states that both increases and decreases in phenytoin concentration have been reported with concomitant use of these agents.<sup>9</sup><br><br>Although not fully investigated, the likely mechanism by which fosphenytoin may decrease dexamethasone levels is phenytoin induction of CYP3A4, an enzyme likely responsible for dexamethasone metabolism. Similarly, dexamethasone induction of CYP3A4 is the likely mechanism for the observed decrease in phenytoin levels. The mechanism by which dexamethasone may increase phenytoin levels is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Haque N, Thrasher K, Werk EE Jr, Knowles HC Jr, Sholiton LJ. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. <i>J Clin Endocrinol Metab</i>. 1972;34(1):44-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5008232\">[PubMed 5008232]</a></p>\n<p>2. Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(10):1087-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502166\">[PubMed 6502166]</a></p>\n<p>3. McLelland J, Jack W. Phenytoin/dexamethasone interaction: A clinical problem. <i>Lancet</i>. 1978;1(8073):1096-1097. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=77390\">[PubMed 77390]</a></p>\n<p>4. Boylan JJ, Owen DS, Chin JB. Letter: Phenytoin interference with dexamethasone. <i>JAMA</i>. 1976;235(8):803-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=946303\">[PubMed 946303]</a></p>\n<p>5. Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M. Phenytoin-dexamethasone: a possible drug-drug interaction. <i>JAMA</i>. 1985;254(15):2062-2063. [4046133]</p>\n<p>6. Recuenco I, Espinosa E, Garcia B, Carcas A. Effect of dexamethasone on the decrease of serum phenytoin concentrations. <i>Ann Pharmacother</i>. 1995;29(9):935. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8547745\">[PubMed 8547745]</a></p>\n<p>7. Lackner TE. Interaction of dexamethasone with phenytoin. <i>Pharmacotherapy</i>. 1991;11(4):344-347. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1923918\">[PubMed 1923918]</a></p>\n<p>8. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB. Phenytoin-dexamethasone interaction: a previously unreported observation. <i>Surg Neurol</i>. 1981;16(1):23-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7280966\">[PubMed 7280966]</a></p>\n<p>9. Dexamethasone [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9137":"<p><b>Title</b> Panobinostat / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid ingestion of grapefruit or grapefruit juice while they are being treated with panobinostat.</p> \n<p><b>Discussion</b> The panobinostat prescribing information cautions that patients should avoid the use of grapefruit juice and any other foods that could inhibit the CYP3A4-mediated metabolism of panobinostat during therapy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9138":"<p><b>Title</b> Panobinostat / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor. Monitor patient response to therapy closely for evidence of more severe adverse effects related to panobinostat therapy.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The panobinostat AUC and maximum serum concentration (Cmax) were increased by an average of 1.8- and 1.6-fold, respectively, with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of 14 patients with cancer who received panobinostat with ketoconazole (400 mg/day).<sup>1</sup><br><br>CYP3A4 is the enzyme primarily responsible for panobinostat metabolism,<sup>2</sup> suggesting that inhibition of CYP3A4 by ketoconazole or other such strong CYP3A4 inhibitors is the likely mechanism for this interaction. The panobinostat prescribing information recommends reducing the panobinostat dose to 10 mg when it must be used with a strong inhibitor of CYP3A4.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hamberg P, Woo MM, Chen LC, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. <i>Cancer Chemother Pharmacol</i>. 2011;68(3):805-813. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21706316\">[PubMed 21706316]</a></p>\n<p>2. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9139":"<p><b>Title</b> Panobinostat / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of strong CYP3A4 inducers in patients being treated with panobinostat.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Models predict an approximate 70% reduction in systemic exposure of panobinostat with concurrent use of a strong CYP3A4 inducer, alhough this potential interaction has not been evaluated in a clinical study.<sup>1</sup><br><br>CYP3A4 is the enzyme primarily responsible for panobinostat metabolism,<sup>1</sup> suggesting that induction of CYP3A4 by strong CYP3A4 inducers is the likely mechanism for this interaction. The panobinostat prescribing information recommends avoiding concurrent use of a strong CYP3A4 inducer with panobinostat.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9140":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Panobinostat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Panobinostat may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index. If such a combination can not be avoided, monitor patients closely for evidence of CYP2D6 substrate toxicity (or decreased effects if the drug is a prodrug activated by CYP2D6).</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The dextromethorphan AUC and maximum serum concentration were 60% and 80% higher, respectively, with concurrent use of panobinostat in a drug interaction study in patients with advanced cancer.<sup>1,2</sup> This effect was highly variable, with an interquartile range for changes in dextromethorphan AUC of 20% to 130%.<br><br>As dextromethorphan is considered a sensitive substrate for CYP2D6, which is primarily responsible for the metabolism of dextromethorphan to dextrorphan, these data suggest panobinostat is weak to moderate inhibitor of CYP2D6. The panobinostat prescribing information recommends avoiding concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. <i>Cancer Chemother Pharmacol</i>. 2013;72(4):747-755. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24013574\">[PubMed 24013574]</a></p>\n<p>2. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9141":"<p><b>Title</b> Corticosteroids (Systemic) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Corticosteroids (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased corticosteroid effects and/or therapeutic failure if combined with a strong CYP3A4 inducer. Increases in corticosteroid dose may be required to maintain steroid effectiveness.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, MethylPREDNISolone, Triamcinolone (Systemic)<br><b>Exceptions</b> Hydrocortisone (Systemic), PrednisoLONE (Systemic), PredniSONE</p>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Several studies have evaluated the impact of strong CYP3A4 inducers on the pharmacokinetics of systemic corticosteroids. In the presence of CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin), methylprednisolone clearance increased 190% to 480%,<sup>1,2</sup> dexamethasone clearance increased 87% to 193%,<sup>3,4,5</sup> prednisolone clearance increased 37% to 94%,<sup>1,6,7,8,9,10,11,12</sup> and hydrocortisone clearance increased 38%.<sup>13</sup> The half-lives of the steroids were shortened by 54% to 71%, 45% to 51%, 27% to 45%, and 35% for methylprednisolone, dexamethasone, prednisolone, and hydrocortisone, respectively.<sup>1,3,4,6,7,8,9,10,11,12,13</sup> In support of these studies, loss of steroid effectiveness or therapeutic failure in the presence of CYP3A4 inducers has been reported with methylprednisolone,<sup>14</sup> dexamethasone,<sup>15,16,17,18</sup> prednisone/prednisolone,<sup>13,19,20,21,22,23,24,25,26,27,28,29,30,31</sup> hydrocortisone,<sup>29,32,33,34,35</sup> fludrocortisone,<sup>36</sup> and betamethasone.<sup>37</sup><br><br>Product labeling for systemic corticosteroid products states that CYP3A4 inducers may enhance the metabolism of corticosteroids and that dose increases may be required.<sup>38,39,40,41,42,43,44,45,46,47</sup><br><br>The mechanism of these potential interactions is likely due to the induction of CYP3A4-mediated corticosteroid metabolism. Although it most steroids undergo CYP3A4 mediated metabolism,<sup>48</sup> the extent to which each available corticosteroid relies on CYP3A4 for metabolism has not been fully described. The magnitude and consistency of the interaction is probably greater with corticosteroids that rely more heavily on CYP3A4 for metabolic elimination (eg, methylprednisolone, dexamethasone).<sup>49</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. <i>Clin Pharmacol Ther</i>. 1987;42(4):424-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3665340\">[PubMed 3665340]</a></p>\n<p>2. Stjernholm MR, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate.<i>J Clin Endocrinol Metab</i>. 1975;41(5):887-893. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1184723\">[PubMed 1184723]</a></p>\n<p>3. Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. <i>N Engl J Med</i>. 1972;286(21):1125-1128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4553339\">[PubMed 4553339]</a></p>\n<p>4. Haque N, Thrasher K, Werk EE Jr, Knowles HC Jr, Sholiton LJ. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. <i>J Clin Endocrinol Metab</i>. 1972;34(1):44-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5008232\">[PubMed 5008232]</a></p>\n<p>5. Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. <i>J Neurol Neurosurg Psychiatry</i>. 1984;47(10):1087-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502166\">[PubMed 6502166]</a></p>\n<p>6. Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. <i>Eur J Clin Pharmacol</i>. 1993;45(3):287-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8276057\">[PubMed 8276057]</a></p>\n<p>7. Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J. Adverse effect of rifampicin administration on steroid-dependent asthma. <i>Am Rev Respir Dis</i>. 1983;128(2):307-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6349444\">[PubMed 6349444]</a></p>\n<p>8. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. <i>Br Med J (Clin Res Ed)</i>. 1983;286(6369):923-925. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6403136\">[PubMed 6403136]</a></p>\n<p>9. Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. <i>Acta Med Scand</i>. 1983;213(5):339-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6880856\">[PubMed 6880856]</a></p>\n<p>10. Bergrem H, Refvem OK. Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. <i>Proc Eur Dial Transplant Assoc</i>. 1983;19:552-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6878255\">[PubMed 6878255]</a></p>\n<p>11. Petereit LB, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. <i>Clin Pharmacol Ther</i>. 1977;22(6):912-916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=923186\">[PubMed 923186]</a></p>\n<p>12. Frey BM, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. <i>Eur J Clin Invest</i>. 1984;14(1):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6230241\">[PubMed 6230241]</a></p>\n<p>13. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. <i>J Clin Endocrinol Metab</i>. 1984;59(6):1204-1206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6490796\">[PubMed 6490796]</a></p>\n<p>14. Lin FL. Rifampin-induced deterioration in steroid-dependent asthma. <i>J Allergy Clin Immunol</i>. 1996;98(6 pt 1):1125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8977517\">[PubMed 8977517]</a></p>\n<p>15. McLelland J, Jack W. Phenytoin/dexamethasone interaction: a clinical problem. <i>Lancet</i>. 1978;1(8073):1096-1097. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=77390\">[PubMed 77390]</a></p>\n<p>16. Boylan JJ, Owen DS, Chin JB. Letter: phenytoin interference with dexamethasone. <i>JAMA</i>. 1976;235(8):803-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=946303\">[PubMed 946303]</a></p>\n<p>17. Gullo D, Gelsomino R, Marturano I, et al. The antiepileptic drug carbamazepine can cause adrenal insufficiency in patients under hormone replacement therapy for congenital adrenal hyperplasia. <i>Hormones (Athens)</i>. 2013;12(3):470-471. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24121390\">[PubMed 24121390]</a></p>\n<p>18. Hancock KW, Levell MJ. Primidone/dexamethasone interaction. <i>Lancet</i>. 1978;2(8080):97-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=78317\">[PubMed 78317]</a></p>\n<p>19. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. <i>Biomed Pharmacother</i>. 1986;40(8):301-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3814762\">[PubMed 3814762]</a></p>\n<p>20. Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. <i>Kidney Int</i>. 1984;25(1):119-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6374250\">[PubMed 6374250]</a></p>\n<p>21. Brooks PM, Buchanan WW, Grove M, Downie WW. Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. <i>Ann Rheum Dis</i>. 1976;35(4):339-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=970991\">[PubMed 970991]</a></p>\n<p>22. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. <i>Arch Intern Med</i>. 1994;154(13):1521-1524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8018008\">[PubMed 8018008]</a></p>\n<p>23. Udwadia ZF, Sridhar G, Beveridge CJ, Soutar C, McHardy GJ, Leitch AG. Catastrophic deterioration in asthma induced by rifampicin in steroid-dependent asthma. <i>Respir Med</i>. 1993;87(8):629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8290748\">[PubMed 8290748]</a></p>\n<p>24. van Marle W, Woods KL, Beeley L. Concurrent steroid and rifampicin therapy. <i>Br Med J</i>. 1979;1(6169):1020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=435934\">[PubMed 435934]</a></p>\n<p>25. Hendrickse W, McKiernan J, Pickup M, Lowe J. Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome. <i>Br Med J</i>. 1979;1(6159):306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=421090\">[PubMed 421090]</a></p>\n<p>26. Dhanoa J, Natu M, Massey S. Worsening of steroid depending bronchial asthma following rifampicin administration. <i>J Assoc Physicians India</i>. 1998;46(2):242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11273129\">[PubMed 11273129]</a></p>\n<p>27. Verma M, Singh T, Chhatwal J, Saini V, Pawar B. Rifampicin induced steroid unresponsiveness in nephrotic syndrome. <i>Indian Pediatr</i>. 1994;31(11):1437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7896353\">[PubMed 7896353]</a></p>\n<p>28. Jain NK, Madan A, Jhamaria JP, Sharma TN, Mathur DK, Singh DP. Rifampicin induced non-responsiveness to steroids in bronchial asthma. <i>Indian J Chest Dis Allied Sci</i>. 1989;31(4):271-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2638668\">[PubMed 2638668]</a></p>\n<p>29. Sehgal VN, Srivastava G. Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy. <i>Int J Dermatol</i>. 1988;27(4):258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3391717\">[PubMed 3391717]</a></p>\n<p>30. Honeybourne D, Longworth S, Shaffer J. Rifampicin causing an exacerbation of pemphigus. <i>Br J Clin Pract</i>. 1987;41(9):937-938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3451779\">[PubMed 3451779]</a></p>\n<p>31. Wassner SJ, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN. Allograft survival in patients receiving anticonvulsant medications. <i>Clin Nephrol</i>. 1977;8(1):293-297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=328199\">[PubMed 328199]</a></p>\n<p>32. Kara C, Ucakturk A, Aydin OF, Aydin M. Adverse effect of phenytoin on glucocorticoid replacement in a child with adrenal insufficiency. <i>J Pediatr Endocrinol Metab</i>. 2010;23(9):963-966. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21175098\">[PubMed 21175098]</a></p>\n<p>33. Hogler W, Wudy SA, Luef G, Hartmann MF, Rauchenzauner M. Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction. <i>Arch Dis Child</i>. 2010;95(12):1065. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20515961\">[PubMed 20515961]</a></p>\n<p>34. Maisey DN, Brown RC, Day JL. Letter: rifampicin and cortisone replacement therapy. <i>Lancet</i>. 1974;2(7885):896-897. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4137806\">[PubMed 4137806]</a></p>\n<p>35. Edwards OM, Courtenay-Evans RJ, Galley JM, Hunter J, Tait AD. Changes in cortisol metabolism following rifampicin therapy. <i>Lancet</i>. 1974;2(7880):548-551. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4140269\">[PubMed 4140269]</a></p>\n<p>36. Keilhoz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. <i>Am J Med Sci</i>. 1986;291(4):280-283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3706393\">[PubMed 3706393]</a></p>\n<p>37. Miyagawa S, Yamashina Y, Okuchi T, Konoike Y, Kano T, Sakamoto K. Exacerbation of pemphigus by rifampicin. <i>Br J Dermatol</i>. 1986;114(6);729-732. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3718864\">[PubMed 3718864]</a></p>\n<p>38. Dexamethasone [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2007.</p>\n<p>39. <i>Solu-Cortef</i> (hydrocortisone) [prescribing information]. New York, NY: Pfizer Inc; August 2012.</p>\n<p>40. <i>Solu-Medrol</i> (methylprednisolone) [prescribing information]. New York, NY: Pfizer Inc; May 2012.</p>\n<p>41. <i>Orapred</i> (prednisolone) [prescribing information]. Florham Park, NJ: Shionogi Inc; March 2011.</p>\n<p>42. Prednisone [prescribing information]. Columbus, OH: Roxane Laboratories Inc; November 2012.</p>\n<p>43. <i>Celestone</i> (betamethasone) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; May 2012. </p>\n<p>44. Cortisone [prescribing information]. Eatontown, NJ: West-Ward Pharmaceutical Corporation; July 2009.</p>\n<p>45. Fludrocortisone [prescribing information]. Sellersville, PA: Barr Laboratories Inc; November 2010. </p>\n<p>46. <i>Aristospan</i> (triamcinolone) [prescribing information]. Princeton, NJ: Sandoz Inc; July 2008.</p>\n<p>47. <i>Calcort</i> (deflazacort) [summary of product characteristics]. Guildford, Surrey, UK: Sanofi-Aventis; July 2014.</p>\n<p>48. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. <i>Arch Biochem Biophys</i>. 1988;263(2):424-436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3259858\">[PubMed 3259858]</a></p>\n<p>49. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. <i>J Pharmacol Exp Ther</i>. 1996;277(1):105-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8613906\">[PubMed 8613906]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9142":"<p><b>Title</b> Panobinostat / Dolasetron</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dolasetron may enhance the arrhythmogenic effect of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note the potential increase in risk for excessive prolongation of the QT interval with use of this combination. According to the panobinostat prescribing information, anti-emetics that may prolong the QT interval, such as dolasetron or ondansetron, can be used with frequent ECG monitoring.</p> \n<p><b>Discussion</b> The panobinostat prescribing information cautions that adverse cardiac effects, including arrhythmias and ECG changes, have been reported with panobinostat.<sup>1</sup> According to a commentary on the QT-prolonging effects of panobinostat, most QTc prolongation was noted with higher dose and/or intravenous administration, and use of orally administered panobinostat three times weekly was associated with a 6.3% incidence of QTc prolongation.<sup>2</sup><br><br>The panobinostat prescribing information states that use with antiarrhythmics or other agents that are known to prolong the QT interval is not recommended, but that use of anti-emetics that may prolong the QT interval, such as dolasetron or ondansetron, is permitted with frequent ECG monitoring.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p>2. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). <i>J Clin Oncol</i>. 2008;26(2):332-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18182676\">[PubMed 18182676]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9143":"<p><b>Title</b> Panobinostat / Granisetron</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Granisetron may enhance the arrhythmogenic effect of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note the potential increase in risk for excessive prolongation of the QT interval with use of this combination. According to the panobinostat prescribing information, anti-emetics that may prolong the QT interval, such as dolasetron or ondansetron, can be used with frequent ECG monitoring.</p> \n<p><b>Discussion</b> The panobinostat prescribing information cautions that adverse cardiac effects, including arrhythmias and ECG changes, have been reported with panobinostat.<sup>1</sup> According to a commentary on the QT-prolonging effects of panobinostat, most QTc prolongation was noted with higher dose and/or intravenous administration, and use of orally administered panobinostat three times weekly was associated with a 6.3% incidence of QTc prolongation.<sup>2</sup><br><br>The panobinostat prescribing information states that use with antiarrhythmics or other agents that are known to prolong the QT interval is not recommended, but that use of anti-emetics that may prolong the QT interval, such as dolasetron or ondansetron, is permitted with frequent ECG monitoring.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p>2. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). <i>J Clin Oncol</i>. 2008;26(2):332-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18182676\">[PubMed 18182676]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9144":"<p><b>Title</b> Panobinostat / Ondansetron</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ondansetron may enhance the arrhythmogenic effect of Panobinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note the potential increase in risk for excessive prolongation of the QT interval with use of this combination. According to the panobinostat prescribing information, anti-emetics that may prolong the QT interval, such as dolasetron or ondansetron, can be used with frequent ECG monitoring.</p> \n<p><b>Discussion</b> The panobinostat prescribing information cautions that adverse cardiac effects, including arrhythmias and ECG changes, have been reported with panobinostat.<sup>1</sup> According to a commentary on the QT-prolonging effects of panobinostat, most QTc prolongation was noted with higher dose and/or intravenous administration, and use of orally administered panobinostat three times weekly was associated with a 6.3% incidence of QTc prolongation.<sup>2</sup><br><br>The panobinostat prescribing information states that use with antiarrhythmics or other agents that are known to prolong the QT interval is not recommended, but that use of anti-emetics that may prolong the QT interval, such as dolasetron or ondansetron, is permitted with frequent ECG monitoring.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Farydak</i> (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.</p>\n<p>2. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). <i>J Clin Oncol</i>. 2008;26(2):332-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18182676\">[PubMed 18182676]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9145":"<p><b>Title</b> Avibactam / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Avibactam. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of avibactam with probenecid is not recommended.</p> \n<p><b>Discussion</b> Probenecid inhibited the uptake of avibactam by OAT1 and OAT3 by 70% and 56%, respectively, in an in vitro study, suggesting that probenecid may increase avibactam concentrations by impairing its renal elimination.<sup>1,2</sup> Because no clinical studies have been conducted to evaluate this potential interaction the ceftazidime-avibactam prescribing information cautions that concurrent use of probenecid is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Avycaz</i> (ceftazidime-avibactam) [prescribing information]. Cincinnati, OH: Forest Pharmaceuticals, Inc.; February 2015.</p>\n<p>2. Vishwanathan K, Mair S, Gupta A, et al. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. <i>Drug Metab Dispos</i>. 2014;42(5):932-942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24616266\">[PubMed 24616266]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9146":"<p><b>Title</b> Azilsartan / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Azilsartan. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required beyond routine blood pressure monitoring that accompanies the use of azilsartan.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the azilsartan product monograph, the administration of fluconazole (dose not stated) increased the azilsartan AUC and maximum serum concentration 42% and 14%, respectively.<sup>1</sup> <br><br>While not fully investigated, inhibition of CYP2C9 by fluconazole, an enzyme thought to play a role in azilsartan metabolism, may be the mechanism of this potential interaction.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Edarbi</i> (azilsartan) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9147":"<p><b>Title</b> Lopinavir / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the QTc-prolonging effect of Lopinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of lopinavir/ritonavir and saquinavir. If the combination cannot be avoided, monitor for QT prolongation and only use the twice-daily dosing regimen for lopinavir/ritonavir (not the once-daily dosing regimen).</p> \n<p><b>Discussion</b> Both saquinavir and lopinavir/ritonavir have been associated with QT prolongation and their concomitant use may result in additive QT prolongation effects.<sup>1,2</sup> Prescribing information for both agents recommends avoidance with other drugs that prolong the QT interval.<sup>1,2</sup><br> <br>Several studies have shown that the combination of saquinavir and lopinavir/ritonavir dosed twice daily did not impact the pharmacokinetics of saquinavir when compared with a saquinavir and ritonavir regimen.<sup>3,4,5</sup> The pharmacokinetics of lopinavir were also unchanged.<sup>3,4,5</sup> In contrast, one study reported reduced saquinavir concentrations with this combination when compared with historical controls receiving saquinavir and ritonavir, but the magnitude and significance of this finding is unknown.<sup>6</sup> Prescribing information states that if these agents are combined, lopinavir/ritonavir should be dosed twice daily because once-daily dosing has not been studied with saquinavir.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>2. <i>Invirase</i> (saquinavir) [prescribing information]. Leganes, Spain: Hoffman-La Roche Inc; November 2012.</p>\n<p>3. Stephan C, von Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. <i>AIDS</i>. 2004;18(3):503-508. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15090803\">[PubMed 15090803]</a></p>\n<p>4. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. <i>Antimicrob Agents Chemother</i>. 2004;48(11): 4256-4262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15504850\">[PubMed 15504850]</a> </p>\n<p>5. Dailly E, Gagnieu MC, Allavena C, Raffi F, Jolliet P. No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach. <i>Ther Drug Monit</i>. 2005;27(6):782-784. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16306855\">[PubMed 16306855]</a></p>\n<p>6. la Porte CJ, Wasmuth JC, Schneider K, Rockstroh JK, Burger DM. Lopinavir/ritonavir plus saquinavir in salvage chemotherapy; pharmacokinetics, tolerability, and efficacy. <i>AIDS</i>. 2003;17(11):1700-1702. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12853756\">[PubMed 12853756]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9148":"<p><b>Title</b> QuiNIDine / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of quinidine and ritonavir. This combination is contraindicated in ritonavir labeling. If the combination cannot be avoided, monitor for increased effects/toxicity of quinidine (eg, QT prolongation, cardiac arrhythmias).</p> \n<p><b>Discussion</b> Ritonavir US prescribing information lists concomitant use with quinidine as contraindicated due to the potential for elevated serum concentrations of quinidine and associated toxicty.<sup>1</sup> Lopinavir/ritonavir prescribing information recommends additional monitoring of quinidine serum concentrations and toxicity if these agents are used in combination, but also recommends to avoid use with other medications that are known to prolong the QT interval (eg, quinidine).<sup>2</sup><br><br>The mechanism of this interaction is likely inhibition of CYP3A4 by ritonavir, an enzyme responsible for quinidine metabolism.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>2. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>3. Quinidine. [prescribing information]. Corona, CA: Watson Pharma Inc; June 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9149":"<p><b>Title</b> QuiNIDine / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may enhance the QTc-prolonging effect of QuiNIDine. Lopinavir may increase the serum concentration of QuiNIDine. Specifically, lopinavir/ritonavir may increase the serum concentration of quinidine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of lopinavir/ritonavir and quinidine. If the combination cannot be avoided, monitor for increased effects/toxicity of quinidine (eg, QT prolongation, cardiac arrhythmias).</p> \n<p><b>Discussion</b> Lopinavir/ritonavir US prescribing information recommends additional monitoring of quinidine serum concentrations and toxicity when these agents are used in combination, due to the potential for elevated serum concentrations of quinidine and associated toxicity.<sup>1</sup> Prescribing information for lopinavir/ritonavir also recommends to avoidance with other drugs that prolong the QT interval (eg, quinidine),<sup>1</sup> and ritonavir prescribing information lists concomitant use with quinidine as contraindicated.<sup>2</sup><br> <br>The mechanism of this interaction is likely inhibition of CYP3A4 by lopinavir/ritonavir, an enzyme responsible for quinidine metabolism.<sup>1,2,3,4</sup> Both lopinavir/ritonavir and quinidine have also been associated with QT prolongation and their concomitant use may result in additive QT prolongation effects.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir/ ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>2. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>3. Quinidine. [prescribing information]. Corona, CA: Watson Pharma Inc; June 2009.</p>\n<p>4. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP3A4 in-vitro by lopinavir. <i>J Pharm Pharmacol</i>. 2003;55(3):381-386. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12724045\">[PubMed 12724045]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9150":"<p><b>Title</b> Disulfiram / Lopinavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only expected with the lopinavir/ritonavir solution, which contains 42% alcohol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may enhance the adverse/toxic effect of Disulfiram. Specifically, the combination of lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-alcohol reaction if combined. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of lopinavir/ritonavir oral solution and disulfiram should be avoided.</p> \n<p><b>Discussion</b> Lopinavir/ritonavir oral solution contains 42.4% alcohol.<sup>1</sup> Lopinavir/ritonavir prescribing information states that a disulfiram-like reaction can occur when the oral solution is co-administered with disulfiram.<sup>1</sup> Disulfiram prescribing information states that it should not be given to patients taking alcohol-containing medication preparations.<sup>2</sup> <br><br>Concomitant therapy with lopinavir/ritonavir oral solution and disulfiram may result in reduced metabolism of the alcohol, subsequent accumulation of acetaldehyde, and lead to a disulfiram-alcohol reaction (eg, flushing, headache, respiratory distress, nausea, vomiting).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>2. <i>Antabuse</i> (disulfiram) [prescribing information]. Pomona, New York: Barr Pharmaceuticals LLC; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9151":"<p><b>Title</b> QuiNIDine / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased quinidine serum concentrations and effects during concomitant atazanavir treatment.</p> \n<p><b>Discussion</b> Atazanavir US prescribing information recommends additional monitoring of quinidine serum concentrations when these agents are used together, due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is atazanavir inhibition of CYP3A-mediated quinidine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9152":"<p><b>Title</b> QuiNIDine / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased quinidine serum concentrations and effects during concomitant darunavir treatment.</p> \n<p><b>Discussion</b> Darunavir US prescribing information recommends additional monitoring of quinidine serum concentrations when these agents are used together, due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is darunavir inhibition of CYP3A-mediated quinidine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Prezista</i> (darunavir) [prescribing information]. Titusville NJ: Janssen Products LP; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9153":"<p><b>Title</b> QuiNIDine / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosamprenavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased quinidine serum concentrations and effects during concomitant fosamprenavir treatment.</p> \n<p><b>Discussion</b> Fosamprenavir US prescribing information recommends additional monitoring of quinidine serum concentrations when these agents are used together, due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is fosamprenavir inhibition of CYP3A-mediated quinidine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lexiva</i> (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9154":"<p><b>Title</b> QuiNIDine / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Indinavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased quinidine serum concentrations and effects during concomitant indinavir treatment.</p> \n<p><b>Discussion</b> Indinavir US prescribing information recommends additional monitoring of quinidine serum concentrations when these agents are used together, due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is indinavir inhibition of CYP3A-mediated quinidine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Crixivan</i> (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9155":"<p><b>Title</b> QuiNIDine / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nelfinavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of nelfinavir and quinidine. Nelfinavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Nelfinavir US prescribing information lists its combination with quinidine as contraindicated due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is nelfinavir inhibition of CYP3A-mediated quinidine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Viracept</i> (nelfinavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare Company; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9156":"<p><b>Title</b> QuiNIDine / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of tipranavir and quinidine. Tipranavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Tipranavir US prescribing information lists its combination with quinidine as contraindicated due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is inhibition of CYP3A-mediated quinidine metabolism by tipranavir and/or coadministered ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc: April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9157":"<p><b>Title</b> QuiNIDine / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the QTc-prolonging effect of QuiNIDine. Saquinavir may increase the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of saquinavir and quinidine. Saquinavir US prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Saquinavir US prescribing information lists its combination with quinidine as contraindicated due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1</sup> The suspected primary mechanism of interaction between these agents is saquinavir inhibition of CYP3A-mediated quinidine metabolism. Independent of a potential pharmacokinetic interaction between these agents, both saquinavir and quinidine have been associated with QTc prolongation and their combined use may result in additive QT prolongation effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invirase</i> (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9158":"<p><b>Title</b> QuiNIDine / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased quinidine serum concentrations and effects during concomitant cobicistat treatment.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products recommends additional monitoring of quinidine serum concentrations when these agents are used together, due to the potential for elevated serum quinidine concentrations and associated toxicity.<sup>1,2,3,4</sup> The suspected primary mechanism of interaction between these agents is cobicistat inhibition of CYP3A-mediated quinidine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. Evotaz (atazanavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. Prezcobix (darunavir/cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9159":"<p><b>Title</b> Bromazepam / Propranolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propranolol may increase the serum concentration of Bromazepam. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In 7 healthy subjects, coadministration of propranolol (80 mg twice daily for 2 days) and bromazepam (6 mg single oral dose) increased the bromazepam half-life 20%, but had no effect on the clearance or maximum serum concentration of bromazepam.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. <i>Clin Pharmacol Ther</i>. 1987;41(5):562-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2882883\">[PubMed 2882883]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9160":"<p><b>Title</b> CISplatin / Alpha-Lipoic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alpha-Lipoic Acid may diminish the therapeutic effect of CISplatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use care when considering the use of alpha-lipoic acid (also known as thioctic acid) with cisplatin. Monitor patient response to cisplatin closely.</p> \n<p><b>Discussion</b> The thioctic acid prescribing information cautions that thioctic acid (alpha-lipoic acid) may impair the effectiveness of cisplatin.<sup>1,2</sup> Specific data in support of this caution is not provided, but the warning may reflect a concern that if thioctic acid is effective at reducing cisplatin toxicities (e.g., neurotoxicity, cardiotoxicity, nephrotoxicity, etc.), which has been investigated in numerous animal and other experimental models, the mechanisms for such a beneficial effect may also impair cisplatin effectiveness.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioctic acid injection [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200501656. Accessed December 1, 2014.</p>\n<p>2. Thioctic acid tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200201478. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9161":"<p><b>Title</b> Alpha-Lipoic Acid / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may diminish the therapeutic effect of Alpha-Lipoic Acid. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving alpha-lipoic acid (also known as thioctic acid) for treatment of diabetic neuropathy should avoid concurrent use of alcohol.</p> \n<p><b>Discussion</b> The thioctic acid prescribing information cautions that alcohol consumption may impair the effectiveness of thioctic acid (alpha-lipoic acid) since alcohol may contribute to the development and progression of diabetic neuropathy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioctic acid injection [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200501656. Accessed December 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9162":"<p><b>Title</b> Alpha-Lipoic Acid / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies only to orally administered alpha-lipoic acid and orally administered iron salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of alpha-lipoic acid (also known as thioctic acid) from that of any iron-containing compounds by several hours to minimize the potential for any interaction. The prescribing information recommends that if alpha-lipoic acid is given 30 minutes before breakfast, then oral iron-containing products should be administered at lunch or dinner.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> The thioctic acid prescribing information cautions that thioctic acid (alpha-lipoic acid) may bind to certain cations (such as iron, magnesium, or calcium) leading to the formation of insoluble complexes.<sup>1</sup> As a result, administration of such compounds should be separated by several hours. The prescribing information recommends that if thioctic acid is given 30 minutes before breakfast, then the iron, magnesium, or calcium compound should be administered at lunch or dinner.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioctic acid tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200201478. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9163":"<p><b>Title</b> Alpha-Lipoic Acid / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies only to orally administered alpha-lipoic acid and orally administered magnesium salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of alpha-lipoic acid (also known as thioctic acid) from that of any magnesium-containing compounds by several hours to minimize the potential for any interaction. The prescribing information recommends that if alpha-lipoic acid is given 30 minutes before breakfast, then any oral magnesium-containing product should be administered at lunch or dinner.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> The thioctic acid prescribing information cautions that thioctic acid (alpha-lipoic acid) may bind to certain cations (such as iron, magnesium, or calcium) leading to the formation of insoluble complexes.<sup>1</sup> As a result, administration of such compounds should be separated by several hourse. The prescribing information recommends that if thioctic acid is given 30 minutes before breakfast, then the iron, magnesium, or calcium compound should be administered at lunch or dinner.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioctic acid tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200201478. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9164":"<p><b>Title</b> Alpha-Lipoic Acid / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies only to orally administered alpha-lipoic acid and orally administered calcium salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of alpha-lipoic acid (also known as thioctic acid) from that of any calcium-containing compounds by several hours to minimize the potential for any interaction. The prescribing information recommends that if alpha-lipoic acid is given 30 minutes before breakfast, then any oral calcium-containing product should be administered at lunch or dinner.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil<br><b>Exception</b> Calcium Chloride</p>\n</div> \n<p><b>Discussion</b> The thioctic acid prescribing information cautions that thioctic acid (alpha-lipoic acid) may bind to certain cations (such as iron, magnesium, or calcium) leading to the formation of insoluble complexes.<sup>1</sup> As a result, administration of such compounds should be separated by several hourse. The prescribing information recommends that if thioctic acid is given 30 minutes before breakfast, then the iron, magnesium, or calcium compound should be administered at lunch or dinner.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioctic acid tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200201478. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9165":"<p><b>Title</b> Lopinavir / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Clarithromycin may enhance the QTc-prolonging effect of Lopinavir. Lopinavir may diminish the therapeutic effect of Clarithromycin. Specifically, lopinavir may decrease the formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness. Lopinavir may increase the serum concentration of Clarithromycin. Clarithromycin may increase the serum concentration of Lopinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of lopinavir/ritonavir and clarithromycin. <br><br>If the combination cannot be avoided, monitor for increased effects/toxicity of clarithromycin, QT interval prolongation, as well as reduced clarithromycin effectiveness/therapeutic failure against non-<i>Mycobacterium avium</i> infections. <br><br>Avoid clarithromycin doses greater than 1,000 mg/day in any patient receiving lopinavir.<sup>1</sup> The clarithromycin dose in patients with impaired renal function receiving concomitant lopinavir/ritonavir should be reduced as follows: CrCl 30-60 ml/min, reduce clarithromycin dose by 50%; CrCl less than 30 ml/min, reduce clarithromycin dose by 75%.<sup>1,2,3</sup> Consider an alternative to clarithromycin for infections other than those caused by <i>Mycobacterium avium</i> complex.<sup>1</sup></p> \n<p><b>Discussion</b> Both lopinavir/ritonavir and clarithromycin have been associated with QT prolongation and their concomitant use may result in additive QT prolongation effects.<sup>1,2</sup> Prescribing information for lopinavir/ritonavir recommends avoidance with other drugs that prolong the QT interval.<sup>2</sup><br><br>In a pharmacokinetic study conducted in 22 healthy volunteers, the AUC, maximum serum concentration (Cmax), and minimum serum concentration (Cmin) of clarithromycin (500 mg every 12 hours) increased 77%, 31%, and 182%, respectively, when coadministered with ritonavir (200 mg every 8 hours) for 4 days.<sup>4</sup> The formation of the 14-hydroxy-metabolite (responsible for some of clarithromycin antimicrobial activity against certain organisms) was almost completely inhibited.<sup>4</sup> The AUC and Cmax of ritonavir increased 13% and 15%, respectively.<sup>4</sup> <br><br>The likely mechanism of these interactions are inhibition of CYP3A4 by ritonavir and clarithromycin, an enzyme responsible for the metabolism of each drug.<sup>2,4</sup> As such, although specific data are not available, the pharmacokinetic changes seen with ritonavir are expected to be similar with lopinavir/ritonavir.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Biaxin</i> (clarithromycin) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>2. <i>Kaletra</i> (lopinavir/ritonavir). North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>3. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>4. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. <i>Clin Pharmacol Ther</i>. 1998;64(4):355-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9797791\">[PubMed 9797791]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9166":"<p><b>Title</b> Isavuconazonium Sulfate / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of isavuconazonium and strong CYP3A4 inhibitors. Isavuconazonium US prescribing information lists this as contraindicated. Lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) is treated as a possible exception to this contraindication despite strongly inhibiting CYP3A4.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, the isavuconazole AUC was 422% higher in 12 healthy volunteers who received ketoconazole (200 mg twice daily x 24 days) and isavuconazole (200 mg single dose) compared with that of 12 subjects who received isavuconazole alone.<sup>1</sup> The isavuconazole maximum serum concentration (Cmax) was 9% higher in particpants who received ketoconazole.<sup>1</sup> In a second study, coadministration of lopinavir/ritonavir (400 mg/100 mg twice daily) increased the Cmax and AUC of isavuconazole (from isavuconazonium sulfate) by 74% and 96%, respectively.<sup>2</sup> AUCs of lopinavir and ritonavir were decreased by 27% and 31%, respectively. <br><br>The suspected primary mechanism of these interactions is inhibition of CYP3A-mediated isavuconazole metabolism by ketoconazole and lopinavir/ritonavir. Isavuconazole may reduce lopinavir and ritonavir exposure by CYP3A induction and, in the case of lopinavir, possibly also interference with ritonavir CYP3A inhibition. Isavuconazole prescribing information lists its use with strong CYP3A4 inhibitors as contraindicated, although some sections of the label treat lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) as a possible exception despite these agents strongly inhibiting CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. Doi: 10.1002/cpdd.285. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273461\">[PubMed 27273461]</a></p>\n<p>2. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9167":"<p><b>Title</b> Isavuconazonium Sulfate / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of isavuconazonium and strong CYP3A4 inducers. Isavuconazonium US prescribing information lists this combination as contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, rifampin (600 mg daily x 35 days) decreased the isavuconazole (400 mg x 1, followed by 100 mg daily x 13 days) maximum serum concentration and AUC 75% and 97%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A-mediated isavuconazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p>2. Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethingdrone in healthy adults [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. Doi: 10.1002/cpdd.285. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273461\">[PubMed 27273461]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9168":"<p><b>Title</b> Isavuconazonium Sulfate / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, St Johns Wort may decrease isavuconazole serum concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of isavuconazonium and St. John's wort. Isavuconazonium US prescribing information lists this as contraindicated.</p> \n<p><b>Discussion</b> In a clinical study summarized in isavuconazonium US prescribing information, coadministration with rifampin (600 mg daily) decreased the maximum concentration and AUC of isavuconazole (from isavuconazonium sulfate) by 79% and 97%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A-mediated isavuconazole metabolism. Isavuconazonium prescribing information lists its use with strong CYP3A inducers as contraindicated, specifically citing St. John's wort as an example inducer.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cresemba</i> (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc: March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9169":"<p><b>Title</b> BuPROPion / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may decrease the serum concentration of BuPROPion. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of reduced bupropion clinical effects with coadministration of isavuconazonium. Bupropion dose increases may be necessary.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy volunteers, isavuconazonium (200 mg three times daily x 2 days, followed by 200 mg daily x 10 days) decreased the bupropion (100 mg daily x 10 days) AUC and maximum serum concentration 42% and 31%, respectively.<sup>1</sup><br><br>Isavuconazonium prescribing information states that concomitant administration of isavuconazonium and bupropion may necessitate a dose increase of bupropion, but the dose of<br>bupropion should not exceed the maximum recommended dose.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is isavuconazole (from isavuconazonium sulfate) induction of CYP2B6-mediated bupropion metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273149\">[PubMed 27273149]</a></p>\n<p>2. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9170":"<p><b>Title</b> Digoxin / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of increased digoxin concentrations and clinical effects with coadministration of isavuconazonium.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 21 healthy volunteers, isavuconazonium (200 mg three times daily x 2 days, followed by 200 mg daily x 10 days) increased the digoxin (0.5 mg single dose) AUC and maximum serum concentration 25% and 33%, respectively.<sup>1</sup> <br><br>Isavuconazonium prescribing information states that concomitant administration of isavuconazonium and digoxin results in an increase in digoxin exposure.<sup>2</sup> Serum digoxin<br>concentrations should be monitored closely when these agents are combined.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is isavuconazole (from isavuconazonium sulfate) inhibition of P-glycoprotein-mediated digoxin efflux.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273004\">[PubMed 27273004]</a></p>\n<p>2. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9171":"<p><b>Title</b> Mycophenolate / Isavuconazonium Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isavuconazonium Sulfate may increase the serum concentration of Mycophenolate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of increased mycophenolate clinical effects with coadministration of isavuconazonium.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 21 healthy volunteers, coadministration of isavuconazole (200 mg three times daily x 2 days, then 200 mg daily x 6 days) and mycophenolate mofetil (1,000 mg single dose) increased the mycophenolic acid AUC 35% and decreased the maximum concentration and AUC of the inactive glucuronide metabolite by 32% and 24%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is isavuconazole (from isavuconazonium sulfate) inhibition of UGT-mediated mycophenolic acid conjugation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults [published online June 8, 2016]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27273343\">[PubMed 27273343]</a></p>\n<p>2. Cresemba (isavuconazonium sulfate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9172":"<p><b>Title</b> Vitamin B12 / Chloramphenicol (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Chloramphenicol may decrease the efficacy of vitamin B12 when used for the treatment of anemia. The use of vitamin B12 for the treatment of cyanide poisoning is unlikely to be affected by chloramphenicol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may diminish the therapeutic effect of Vitamin B12. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of vitamin B12, when used for the treatment of anemia, if combined with chloramphenicol. Use of high-dose vitamin B12 for the treatment of cyanide poisoning is unlikely to be affected by cholramphenicol therapy.</p>\n<div>\n <p><b>Vitamin B12 Interacting Members</b> Cobamamide, Cyanocobalamin, Hydroxocobalamin, Methylcobalamin</p>\n</div> \n<p><b>Discussion</b> In one small study, 4 patients with pernicious anemia were given 3 to 4 g of chloramphenicol daily for 3 to 7 days along with vitamin B12 (30 mcg intramuscular daily).<sup>1</sup> In 2 patients, chloramphenicol was given after the initiation of vitamin B12, in 1 patient chloramphenicol was given 3 days prior to vitamin B12, and in 1 patient the two agents were administered simultaneously. In each case, chloramphenicol either interrupted or delayed the reticulocyte response to vitamin B12. Vitamin B12 response was restored in all patients after chloramphenicol discontinuation.<sup>1</sup><br><br>The exact mechanism of this interaction is unknown, but chloramphenicol may inhibit red blood cell maturation and prevent anemia resolution despite treatment with vitamin B12.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Saidi P, Wallerstein RO, Aggeler PM. Effect of chloramphenicol on erythropoiesis. <i>J Lab Clin Med</i>. 1961;57:247-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13745416\">[PubMed 13745416]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9173":"<p><b>Title</b> Antidiabetic Agents / Alpha-Lipoic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alpha-Lipoic Acid may enhance the hypoglycemic effect of Antidiabetic Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of hypoglycemia during concurrent use of alpha-lipoic acid (also known as thioctic acid) with antidiabetic drugs. The risk for any significant interaction may be greatest immediately following initiation of the combination. Intravenous alpha-lipoic acid may have a greater impact on serum glucose than oral products. In some cases, the dose of insulin or oral antidiabetic drugs may need to be reduced to avoid hypoglycemia.</p>\n<div>\n <p><b>Antidiabetic Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, ChlorproPAMIDE, Dapagliflozin, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, MetFORMIN, Miglitol, Mitiglinide, Nateglinide, Pioglitazone, Pramlintide, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> The thioctic acid prescribing information cautions that thioctic acid (alpha-lipoic acid) may increase the glucose-lowering actions of antidiabetic agents, possibly increasing the risk for hypoglycemia and requiring a dose reduction of concurrent antidiabetic agents.<sup>1,2</sup><br><br>Several studies in patients with type II diabetes have demonstrated that alpha-lipoic acid reduces fasting glucose by up to 18%.<sup>3,4,5</sup> According to a review of the subject, parenteral alpha-lipoic acid has a more significant effect than does oral alpha-lipoic acid.<sup>6</sup> Conversely, other studies have concluded that alpha-lipoic acid does not significantly enhance the glucose-lowering effects of the antidiabetic agents insulin, glibenclamide, or acarbose.<sup>7,8</sup><br><br>The mechanism for this possible interaction is unclear. Alpha-lipoic acid administration has been associated with a 30% to 50% increase in insulin-stimulated glucose disposal.<sup>9,10</sup> Although the specific mechanism by which this effect occurs is not known, antioxidant effects and protein kinase activating properties have been discussed as possibly relevant mechanisms.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioctic acid tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200201478. Accessed September 1, 2014.</p>\n<p>2. Thioctic acid injection [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200501656. Accessed December 1, 2014.</p>\n<p>3. Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. <i>Asia Pac J Clin Nutr</i>. 2012;21(1):12-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22374556\">[PubMed 22374556]</a></p>\n<p>4. Ansar H, Mazloom Z, Kazemi F, Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. <i>Saudi Med J</i>. 2011;32(6):584-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21666939\">[PubMed 21666939]</a></p>\n<p>5. Negrisanu G, Rosu M, Bolte B, Lefter D, Dabelea D. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. <i>Rom J Intern Med</i>. 1999;37(3):297-306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15532308\">[PubMed 15532308]</a></p>\n<p>6. Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. <i>Diabetes Technol Ther</i>. 2000;2(3):401-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11467343\">[PubMed 11467343]</a></p>\n<p>7. Gleiter CH, Schreeb KH, Freudenthaler S, et al. Lack of interaction between thioctic acid, glibenclamide and acarbose. <i>Br J Clin Pharmacol</i>. 1999;48(6):819-825. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594485\">[PubMed 10594485]</a></p>\n<p>8. Huang Z, Wan X, Liu J, et al. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. <i>Diabetes Technol Ther</i>. 2013;15(10):859-869. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23991629\">[PubMed 23991629]</a></p>\n<p>9. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. <i>Exp Clin Endocrinol Diabetes</i>. 1996;104(3):284-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8817248\">[PubMed 8817248]</a></p>\n<p>10. Jacob S, Henriksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. <i>Arzneimittelforschung</i>. 1995;45(8):872-874. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7575750\">[PubMed 7575750]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9174":"<p><b>Title</b> Oxybutynin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs of increased oxybutynin effects/toxicity (eg, anticholinergic effects) if combined with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Oxybutynin prescribing information states that mean oxybutynin plasma concentrations were approximately 2-fold higher when coadministered with the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup> In a pharmacokinetic study conducted in 10 healthy volunteers, the AUC and maximum serum concentration (Cmax) of oxybutynin (5 mg single dose) increased by 1.8- and 1.9-fold, respectively, when coadministered with the strong CYP3A4 inhibitor itraconazole (200 mg once daily for 4 days).<sup>2</sup> The AUC and Cmax of the active metabolite N-desethyloxybutynin were unchanged. <br><br>Oxybutynin prescribing information states that concomitant use with inhibitors of CYP3A4 may alter the AUC and Cmax of oxybutynin.<sup>1</sup> The clinical relevance of these pharmacokinetic changes are unknown, but additional caution and monitoring for increased oxybutynin effects is recommended.<sup>1</sup> <br><br>The likely mechanism of this interaction is the inhibition of CYP3A4-mediated oxybutynin metabolism by strong CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ditropan XL</i> (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015.</p>\n<p>2. Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ. Itraconazole moderately increases the serum concentrations of oxybutynin but does not affect those of the active metabolite. <i>Eur J Clin Pharmacol</i>. 1997;52(5):403-406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9272412\">[PubMed 9272412]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9176":"<p><b>Title</b> Ivacaftor / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Ivacaftor. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid ingestion of bitter orange or Seville oranges during treatment with ivacaftor.</p> \n<p><b>Discussion</b> US prescribing information for ivacaftor recommends that patients avoid consumption of bitter orange or Seville oranges while taking ivacaftor.<sup>1</sup> Since ivacaftor is a CYP3A4 substrate<sup>1</sup> and bitter orange and Seville oranges are thought to be weak inhibitors of CYP3A4,<sup>2,3</sup> their combined use may result in increased ivacaftor exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kalydeco</i> (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; March 2015.</p>\n<p>2. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. <i>Clin Pharmacol Ther</i>. 2001;69(1):14-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180034\">[PubMed 11180034]</a></p>\n<p>3. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. <i>Clin Pharmacol Ther</i>. 2005;78(6):605-618. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16338276\">[PubMed 16338276]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9177":"<p><b>Title</b> Warfarin / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Linezolid may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of increased warfarin response (e.g., INR/PT, signs or symptoms of bleeding, etc.) both during and immediately following concurrent use of linezolid. Warfarin dosage adjustments may be needed to achieve or maintain goal INR/PT levels.</p> \n<p><b>Discussion</b> According to a published report of 6 warfarin-treated patients who were recovering from heart-related surgeries, each patient's INR/PT increased following the initiation of concomitant linezolid (from an average of 1.6 to an average of 3.0 at day 4 or 5 following initiation of linezolid) and significantly decreased at the completion of linezolid (from an average of 1.7 after linezolid to 1.3 one week later).<sup>1</sup> Linezolid initiation in 16 patients maintained on a stable dose of warfarin status post left ventricular assist system placement resulted in a nonsignificant increase in mean INR from 3.74 to 4.06.<sup>2</sup> The decrease in mean daily warfarin dose from 3.23 to 2.69, however, was significant. The mean PT-INR to warfarin dose ratio increased from 1.37 to 1.83 at 10 days of concomitant therapy.<sup>2</sup><br><br>Linezolid has not been shown to significantly impact hepatic drug metabolism, making it unlikely that this observed interaction between warfarin and linezolid is due to altered warfarin metabolism. However, linezolid, like other antibiotics, may potentiate the effects of warfarin by lowering the level of intestinal vitamin K producing bacteria, resulting in an increased INR/PT. However, the clinical significance of this effect is still debatable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sakai Y, Naito T, Arima C, et al. Potential drug interaction between warfarin and linezolid. <i>Intern Med</i>. 2015;54(5):459-464. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25758070\">[PubMed 25758070]</a></p>\n<p>2. Kinoshita S, Wada K, Matsuda S, et al. Interaction between warfarin and linezolid in patients with left ventricular assist system in Japan. <i>Intern Med</i>. 2016;55(7):719-724. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27041154\">[PubMed 27041154]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9194":"<p><b>Title</b> Warfarin / Chondroitin Sulfate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chondroitin Sulfate may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of increased warfarin effects (eg, elevated INR, easy bruising or bleeding) in patients receiving glucosamine, chondroitin, or their combination (particularly in higher doses).</p> \n<p><b>Discussion</b> Two published case reports describe elderly patients (69 to 71 years of age) with atrial fibrillation who were receiving stable warfarin doses with INRs within target range for at least several months. The patients' INRs increased to above 4.5 following initiation or dose increase of glucosamine/chondroitin (3 g/2.4 g daily when INR changes were noted in both cases).<sup>1,2</sup> INRs within target range were reestablished following warfarin dose reductions. Glucosamine/chondroitin was discontinued in only one case. One of these reports also summarizes data from the FDA Adverse Event Reporting System describing 20 patients who experienced elevated INR and/or other evidence of increased warfarin effects (eg, bleeding, bruising, hematoma) while taking warfarin with glucosamine, chondroitin, or their combination.<sup>2</sup><br><br>The mechanism of this possible interaction is unclear. Both glucosamine and chondroitin, as chemical components of heparin and danaparoid, respectively, may have some limited anticoagulant activity.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rozenfeld V, Crain JL, Callahan AK. Possible augmentation of warfarin effect by glucosamine-chondroitin. <i>Am J Health Syst Pharm</i>. 2004;61(3):306-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14986566\">[PubMed 14986566]</a></p>\n<p>2. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. <i>Pharmacotherapy</i>. 2008;28(4):540-548. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18363538\">[PubMed 18363538]</a></p>\n<p>3. Weimann G, Lubenow N, Selleng K, Eichler P, Albrecht D, Greinacher A. Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia. <i>Eur J Haematol</i>. 2001;66(3):195-199. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11350488\">[PubMed 11350488]</a></p>\n<p>4. Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. <i>Drugs</i>. 1997;54(6):903-924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9421696\">[PubMed 9421696]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9195":"<p><b>Title</b> Olaparib / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Olaparib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid ingestion of bitter orange or Seville oranges during treatment with olaparib.</p> \n<p><b>Discussion</b> US prescribing information for olaparib recommends that patients avoid consumption of bitter orange or Seville oranges while taking olaparib.<sup>1</sup> Since olaparib is a CYP3A4 substrate<sup>1</sup> and bitter orange and Seville oranges are thought to be weak inhibitors of CYP3A4,<sup>2,3</sup> their combined use may result in increased olaparib exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lynparza</i> (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2014. </p>\n<p>2. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. <i>Clin Pharmacol Ther</i>. 2001;69(1):14-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180034\">[PubMed 11180034]</a></p>\n<p>3. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. <i>Clin Pharmacol Ther</i>. 2005;78(6):605-618. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16338276\">[PubMed 16338276]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9196":"<p><b>Title</b> Ibrutinib / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Ibrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid ingestion of bitter orange or Seville oranges during treatment with ibrutinib.</p> \n<p><b>Discussion</b> US prescribing information for ibrutinib recommends that patients avoid consumption of bitter orange or Seville oranges while taking ibrutinib.<sup>1</sup> Since ibrutinib is a CYP3A4 substrate<sup>1</sup> and bitter orange and Seville oranges are thought to be weak inhibitors of CYP3A4,<sup>2,3</sup> their combined use may result in increased ibrutinib exposure and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Imbruvica</i> (ibrutinib) [prescribing information]. Sunnyvale, CA: Pharmacyclics Inc; January 2015.</p>\n<p>2. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. <i>Clin Pharmacol Ther</i>. 2001;69(1):14-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180034\">[PubMed 11180034]</a></p>\n<p>3. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. <i>Clin Pharmacol Ther</i>. 2005;78(6):605-618. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16338276\">[PubMed 16338276]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9197":"<p><b>Title</b> Disulfiram / Ritonavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only expected with the ritonavir oral solution, which contains 43% alcohol.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may enhance the adverse/toxic effect of Disulfiram. Specifically, the combination of ritonavir oral solution, which contains 43% alcohol, may result in a disulfiram-alcohol reaction if combined. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The concomitant use of ritonavir oral solution and disulfiram should be avoided.</p> \n<p><b>Discussion</b> Ritonavir oral solution contains 43.2% alcohol.<sup>1</sup> Ritonavir prescribing information states that a disulfiram-like reaction can occur when the oral solution is co-administered with disulfiram.<sup>1</sup> Disulfiram prescribing information states that it should not be given to patients taking alcohol-containing medication preparations.<sup>2</sup> <br><br>Concomitant ritonavir oral solution and disulfiram therapy may result in reduced metabolism of the alcohol and subsequent accumulation of acetaldehyde, leading to a disulfiram-alcohol reaction (eg, flushing, headache, respiratory distress, nausea, vomiting).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>2. <i>Antabuse</i> (disulfiram) [prescribing information]. Pomona, New York: Barr Pharmaceuticals LLC; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9198":"<p><b>Title</b> MetroNIDAZOLE (Systemic) / Ritonavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is most likely with the ritonavir oral solution, which contains 43% alcohol, but the soft gelatin capsule may also be subject to the interaction as it also contains alcohol. The ritonavir tablet is not expected to participate in the interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Specifically, the combination of ritonavir oral solution or ritonavir soft gelatin capsule, both of which contain alcohol, and metronidazole may result in a disulfiram-like reaction. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of ritonavir oral solution with metronidazole or within 3 days after stopping metronidazole should be avoided. Similarly, the ritonavir soft gelatin capsules have ethanol as a listed ingredient and should likely also be avoided if possible. Concomitant use may result in a disulfiram-like reaction. Ritonavir tablets do not list alcohol or propylene glycol as an ingredient and may be an alternative to consider in some patients.</p> \n<p><b>Discussion</b> Ritonavir oral solution contains 43.2% alcohol and 26.6% propylene glycol.<sup>1</sup> The ritonavir soft gelatin capsules also have ethanol as a listed ingredient, but the specific amount ingested with recommended doses is unknown.<sup>2</sup> Ritonavir prescribing information cautions that ritonavir products contain alcohol and that a disulfiram-like reaction can occur when co-administered with metronidazole.<sup>1,2</sup> Metronidazole prescribing information states that alcohol consumption or products that contain propylene glycol should not be used during, and for 3 days after, treatment with metronidazole.<sup>3</sup> <br><br>Concomitant use of an alcohol-containing ritonavir product with metronidazole may result in reduced metabolism of the alcohol and subsequent accumulation of acetaldehyde, leading to a disulfiram-like reaction (e.g., flushing, headache, respiratory distress, nausea, vomiting).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Norvir (ritonavir) tablet, solution [prescribing information]. North Chicago, IL: AbbVie Inc.; November 2015.</p>\n<p>2. Norvir (ritonavir) capsule [prescribing information]. North Chicago, IL: AbbVie Inc.; November 2015.</p>\n<p>3. Flagyl (metronidazole) [prescribing information]. New York, NY: Pfizer Inc; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9199":"<p><b>Title</b> Pentoxifylline / CYP1A2 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pentoxifylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased pentoxifylline effects during concomitant treatment with strong CYP1A2 inhibitors.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Strong) Interacting Members</b> FluvoxaMINE</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, the moderate CYP1A2 inhibitor ciprofloxacin (750 mg single oral dose) increased the AUC of pentoxifylline (300 mg single intravenous dose administered over 1 hour) and the R and S isomers of its active M1 metabolite by 31%, 48%, and 36%, respectively.<sup>1</sup> <br><br>Pentoxifylline prescribing information states that strong CYP1A2 inhibitors may increase exposure to pentoxifylline and lead to increased adverse effects.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is ciprofloxacin inhibition of CYP1A2-mediated pentoxifylline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P. A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans. <i>Br J Clin Pharmacol</i>. 2006;61(2):138-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16433868\">[PubMed 16433868]</a></p>\n<p>2. Trental (pentoxifylline) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}